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SUMMARY
There are a limited number of models available suitable for the study of 
adult human bone cell function. Primary cultures of human osteoblast-like 
cells derived from explants of trabecular bone display all the hallmarks of 
mature osteoblasts. The cells express the bone isoenzyme alkaline 
phosphatase and produce type I collagen and other noncollagenous matrix 
proteins. The most osteoblast-specific of these is osteocalcin, a matrix 
protein produced by osteoblasts in response to 1,25-dihydroxyvitamin D3 . 
Explant cultures consist of heterogeneous populations of cells and are slow 
growing making them difficult to obtain in large numbers.
Primary cultures of trabecular bone-derived cells were transfected with 
simian virus 40 DNA and a series of rapidly-growing cell lines were 
obtained. The cell lines were characterised for expression of alkaline 
phosphatase, production of bone matrix proteins osteocalcin, osteonectin, 
bone sialoprotein and thrombospondin, and expression of mRNA for type I 
collagen. The ability of the cells to produce a mineralised matrix was 
assessed by von Kossa and Alizerin Red staining.
Seven cell lines were further characterised for the expression of SV40 T 
antigens and for incorporation of the vector into host cell DNA. The ability of 
these cell lines to produce interleukin 1 , interleukin 6 and tumour necrosis 
factor was assessed. The effects of oestrogen on cytokine production and 
on expression of mRNA for transforming growth factor p were monitored.
The cell lines closely resembled the parent cell phenotype with respect to 
expression of alkaline phosphatase, production of bone matrix proteins, and 
cytokine responsiveness. The phenotype was stable for fifteen passages 
and then declined; the cells entered crisis and eventually senesced. Two 
cell lines obtained by limiting dilution cloning may represent stable post­





1.1 Bone as an organ
1 .1.1 The characteristics and structure of bone.
The skeletal system of vertebrates is composed of two highly specialised 
connective tissues, namely bone and cartilage. Bone is a highly vascular, 
mineralised connective tissue remarkable for its hardness, resilience and 
regenerative capacity. Bone provides structural support for the body and 
serves to protect vital organs such as the central nervous system, heart and 
lungs. Cartilage covering the extremities of the bones provides a smooth 
articular surface permitting frictionless movement of the joints. Bone, in 
addition to its mechanical role, serves a metabolic function as a vital reserve 
of calcium and phosphate ions readily mobilised for the maintenance of 
mineral homeostasis.
Bone consists of an extracellular matrix synthesised and secreted by 
osteoblasts which are the bone forming cells. The matrix is composed of 
type I collagen and numerous other noncollagenous proteins. The 
extracellular matrix of bone, unlike other connective tissue matrices, is 
physiologically mineralised with crystals of a basic, carbonate-containing 
calcium phosphate called hydroxyapatite. Deposition of hydroxyapatite 
crystals occurs following the laying down of collagen fibers. Mineralisation 
of the extracellular matrix gives bone its characteristic hardness and 
strength.
1.1.2 Woven and lamellar bone
Three types of bone are identified according to their structure: these are 
woven bone, cortical bone, and cancellous or trabecular bone. Woven bone 
is the first type of bone to appear in the developing foetus. Here the 
collagen fibers are orientated randomly as irregular bundles and 
calcification occurs in disorganised patches. This is an immature form of 
bone and is resorbed and replaced by more organised lamellar bone during 
development. Woven bone may also appear during fracture healing and in
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certain pathological conditions such as metabolic bone diseases and 
tumours.
Lamellar bone constitutes highly organised and mature bone. Collagen 
fibers are laid down in a preferential direction and the direction alternates 
from layer to layer forming lamellae. Lamellae are parallel if deposited on a 
flat surface such as the periosteum and trabeculae, and concentric on the 
inner surface of the channels through which blood vessels pass. Dense, 
cortical bone in transverse section is seen to consist of concentric rings of 
lamellar bone penetrated by blood vessels, forming the characteristic 
Haversian systems. As bone formation and calcification progress 
osteoblasts become embedded in the matrix forming osteocytes that lie 
within lacunae. The osteocytes have long cytoplasmic extensions which lie 
in channels or canaliculi. These extensions may serve to supply the 
osteocyte with nutrients from the blood or provide communication channels 
with osteoblasts on the surface of bone.
Trabecular bone has a less well defined Haversian system. Its structure is 
that of a honeycomb-like network of bone filaments enclosing spaces that 
are filled with haemopoietic bone marrow. The trabecular structure provides 
a vast surface area of bone available for remodeling. Bone is constantly in a 
dynamic state and is remodelled to provide calcium and phosphate ions 
essential to the maintenance of mineral homeostasis. Compact cortical 
bone provides support and because of its relatively slow turnover is 
probably less important in mineral homeostasis.
1.1.3 Intramembranous and endochondrial ossification.
In the developing embryo the flat bones (mandible, ileum, scapula, skull 
bones) develop by a process of intramembranous ossification. Cells of 
mesenchymal origin cluster together, divide, and differentiate into 
preosteoblasts and osteoblasts. These osteoblasts secrete a matrix of 
collagen, proteoglycans and glycoproteins which is subsequently
3
mineralised. This initial trabeculum, lined by osteoblasts, branches into 
other trabeculae by apposition. As trabeculae widen, osteoblasts are 
included in the matrix as osteocytes. The early woven bone is resorbed by 
osteoclasts and replaced by mature lamellar bone. Those trabeculae 
destined to form compact bone continue to expand, incorporating blood 
vessels into Haversian canals.
The long bones (femur, tibia, humerus) are formed principally by a process 
of endochondral ossification which involves partial replacement of a 
cartilagenous model by bone. Clusters of primitive mesenchymal cells 
divide and differentiate into prechondroblasts and then chond rob lasts.
These cells produce a cartilagenous matrix composed of type II collagen 
and mucopolysaccharides. At the external surface (the perichondrium) 
mesenchymal cells continue to proliferate and differentiate into osteoblasts. 
Woven bone is formed and calcified and is penetrated by blood vessels and 
bone resorbing osteoclasts. Chondroblasts that have become embedded in 
the cartilagenous matrix are termed chondrocytes, they lie within lacunae 
but are still able to proliferate. New matrix is synthesised interstitially 
between chondrocytes and ossification occurs transforming cartilage to 
bone. Intramembranous ossification, not preceded by cartilage, occurs in 
the periosteal region of the diaphysis of long bones and on the walls of the 
Haversian canals that carry blood vessels.
1.1.4 Growth of the long bone
A typical long bone consists of a central cylindrical core (diaphysis) of 
dense and compact cortical bone enclosing the medullary cavity which is 
filled with haemopoietic bone marrow. The dense cortical bone of the 
diaphysis is thinner approaching the two wider extremities (epiphysis) and 
here the internal space is filled with trabecular bone. The diaphysis and 
epiphysis are linked by an intermediate zone, the metaphysis. The
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metaphysis and epiphysis are separated in growing long bones by a layer of 
cartilage making up the growth plate. The cartilagenous growth plate 
continues to proliferate, allowing length increases of the bones, and is only 
replaced when the growth of the bone ceases. As longitudinal growth 
occurs the epiphysis is resorbed externally to form the diaphysis which 
grows by new bone formation at the external surface and by resorption to 
expand the internal cavity. In this way, resorption and formation activities 
maintain the shape of the long bone during growth (Figure 1.1). The 
anatomy, ultrastructure, and development of bone are reviewed by Baron 
(1990) and Teitelbaum (1990).
1.2 The proteins of bone matrix.
The major constituent of connective tissue extracellular matrix is collagen. 
Bone differs from other connective tissues in its ability to become 
mineralised under physiological conditions. The organic matrix of bone 
contains many noncollagenous proteins which may function as instigators 
and/or regulators of the mineralisation process.
1 .2.1 Collagen
Collagen is the most abundant component of bone matrix, comprising 85- 
90% of total bone protein. This protein has a high tensile strength and gives 
strength to various tissues and organs. More than ten types of collagen 
have been identified so far but the collagen of bone is almost exclusively 
type I. The type I collagen molecule is a supercoiled triple helix composed 
of two identical ai (I) chains and one a2 (I) chain which has a slightly 
different amino acid composition. The collagen chains have a unique 
repeating sequence of three amino acids -Gly-X-Y- where X and Y are often 
proline or its hydroxylated derivative, hydroxyproline.
The three constituent a chains of collagen are synthesised simultaneously 
and after translation hydroxylation of certain proline and lysine residues
5
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Fig. 1.1 Resorption (-) and formation (+) activities during the longitudinal 
growth of bones: During the growth from A to B, the cortex in the diaphysis 
must be resorbed inside and reformed outside. The wider parts of the bone 
must be reshaped into a diaphysis (from Baron, 1990).
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occurs. Hydrogen bonds are formed between hydroxyl groups stabilising 
the super helix. Collagen is secreted as a precursor molecule procollagen 
which has non-helical terminal peptides. These telopeptide extensions are 
cleaved following secretion of the molecule, leaving short non-helical 
regions of 15-30 amino acids at each terminal of the collagen molecule. 
When the triple a-chain molecules aggregate to form fibers, strong covalent 
bonds are formed between the non-helical terminal portions of the a chains 
and the helical region of an adjacent molecule. The cross-links are formed 
by oxidative deamination of specific lysine or hydroxylysine residues in the 
non-helical N- and C- telopeptides by a copper-dependent amino-oxidase 
enzyme, lysyl oxidase.
In bone, cartilage, tendon, and most other connective tissues except skin, 
two 3-hydroxypyridinium amino acids, each linking three collagen molecules 
have been identified (Eyre and Oguchi, 1980). Hydroxylysylpyridinoline is 
present as the major component in all these tissues. Lysylpyridinoline is 
present at relatively high concentrations in bone and dentine, and its 
presence in urine has been used as an indicator of bone resorption in 
patients with rheumatoid arthritis and osteoarthritis (Robins etal, 1986), and 
osteoporosis (Delmas etal, 1991).
In mature, lamellar bone, collagen fibers are arranged in parallel layers 
and provide the substratum for deposition of hydroxyapatite crystals and 
calcification of the extracellular matrix. Transmission electron micrographs 
of individual, mineralised collagen fibrils show that hydroxyapatite crystals 
are located mainly within the fibrils at the level of the gap regions (Weiner 
and Traub, 1986).
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1.2.2 Noncollaaenous proteins of bone 
SL Osteocalcin
Price et al (1976) and Hauschka, Lian and Gallop (1975) independently 
described a protein extracted from bone matrix which contained three 
residues of the calcium-binding amino acid y-carboxyglutamate (Gla). 
Sequence analysis of the amino-terminal residues established that the 
novel protein was not a fragment of Gla-containing blood clotting factors.
The protein was demonstrated in bovine dentine, human tibia and swordfish 
vertebrae, but not in tooth enamel. Bone Gla protein (osteocalcin) has a 
molecular weight of 5300 daltons and a single disulphide bond; it binds 
strongly and reversibly to hydroxyapatite but fails to bind collagen or 
amorphous calcium phosphate.
Osteocalcin is synthesised in a precursor form; cleavage of a 23-residue 
transmembrane signal peptide yields a 10kDa pre-pro-osteocalcin molecule 
which is post-translationally modified by the vitamin K-dependent and CO2- 
requiring carboxylation of glutamic acid residues (Lian and Friedman, 1978). 
Osteocalcin is a potent inhibitor of hydroxyapatite crystal growth in vitro at 
physiological pH and ionic strength, the inhibitory activity is decreased by 
thermal decarboxylation of Gla residues (Romberg etal, 1986). Rats treated 
with the vitamin K antagonist warfarin, which reduces bone levels of 
osteocalcin to less than 2 % of normal, displayed an excessive 
mineralisation disorder characterised by a loss of longitudinal growth and a 
densely calcified growth plate (Price etal, 1982). No other skeletal defects 
were observed suggesting that osteocalcin may serve an in vivo role as a 
regulator of mineralisation by inhibiting crystal growth.
Northern analysis of extracted mRNA and immunocytochemical studies 
demonstrate that osteocalcin is mineralised tissue specific and occurs in 
young osteoblasts and odontoblasts (Bronckers etal, 1985; 1987). Several 
osteosarcoma cell lines and non-transformed cultures of osteoblasts
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synthesise osteocalcin and its production is transcriptionally regulated by
1,25-dihydroxyvitamin D3 (1.25D) (Price and Baukol, 1980; Beresford etal, 
1984). In addition, osteocalcin has been shown to be chemotactic for two 
rat osteoblastic osteosarcoma cell lines, ROS and UMR (Lucas, Price and 
Caplan, 1988). Osteocalcin is bound exclusively to mineral and its release 
during demineralisation may serve to recruit osteoblast precursors, thus 
initiating a new round of bone formation.
A small fraction of bone osteocalcin is present in the circulation and 
measurement of serum levels provides a potentially useful indicator of bone 
formation. Serum osteocalcin values are highly correlated with 
histomorphometric measurements of bone formation in primary and 
secondary hyperparathyroidism and postmenopausal osteoporosis 
(Gundberg-Carpenter and Lian, 1989). 
bL Thrombospondin
Thrombospondin is a trimeric molecule, with a molecular weight of 
450kDa, composed of inter and intramolecular disulphide linked monomeric 
subunits of 150kDa. It is the most abundant protein of platelet a granules 
and is secreted when platelets are stimulated with thrombin. The protein is a 
biosynthetic product of a variety of connective tissue cells. More recently, 
thrombospondin has been identified as a secretory product of human 
osteoblast-like cells and as a constituent of bone matrix (Gehron Robey et al, 
1989). The molecule has a stalk region containing a collagen binding site 
and a carboxy globular domain with a Ca2+ binding region.
Thrombospondin is widely distributed in a number of tissues and in 
general is present during stages of cellular proliferation, migration, and 
intercellular adhesion. Thrombospondin mediates bone cell attachment, but 
not spreading in vitro (Gehron Robey etal, 1989). Proposed functions for 
this molecule include the organisation of extracellular matrix components 
and action as an autocrine growth factor.
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Ql Osteopontin
Osteopontin is an acidic, phosphorylated glycoprotein of 41,500 daltons, 
rich in aspartic acid, glutamic acid and serine. A study of the tissue 
specificity of rat osteopontin mRNA demonstrated abundant expression in 
bone and a high expression in kidney. Much lower levels were observed in 
brain and lung, and no osteopontin mRNA was detected in heart, intestine, 
liver, muscle, skin, spleen, cartilage or testes (Yoon, Buenaga and Rodan, 
1987). Immunohistochemical studies demonstrate the synthesis of 
osteopontin by preosteoblasts, osteoblasts and osteocytes, and its 
localisation in osteoid. Osteopontin is also synthesised by sensory and 
neural cells of the inner ear, by odontoblasts and hypertrophic cartilage. 
Strong immunostaining during the early stages of bone formation, prior to 
the deposition of mineral, was observed in developmental studies of rat 
foetuses. These findings are reviewed by Butler (1989). 1,25D and 
transforming growth factor p (TGFp) increase osteopontin production by ROS 
17/2.8 cells and TGFp increases its production in the murine clonal 
osteoblast-like cell line MC3T3-E1 (Noda et al, 1988). However, parathyroid 
hormone (PTH) suppresses osteopontin production and the level of mRNA 
in ROS 17/2.8 (Noda and Rodan, 1989).
Complementary DNA for osteopontin predicts an amino acid sequence of 
Gly-Arg-Gly-Asp-Ser which is identical to a cell binding sequence in 
fibronectin. This sequence has been shown to play a role in cell attachment 
by binding to cell surface integrins. Oldberg, Franzen and Heinegard (1986) 
have shown that osteopontin promotes attachment and spreading of ROS 
17/2.8 cells and this attachment was specifically inhibited by an RGD- 
containing peptide. Immunolocalisation studies by Reinholt eta l (1990) 
demonstrated the presence of osteopontin at the clear zone of the osteoclast 
plasma membrane, much less staining was observed at the ruffled border 
and deeper within the bone. Highest expression of the vitronectin receptor
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was also observed at the clear zone, suggesting that osteopontin may 
function as an anchor of osteoclasts to bone by binding to the vitronectin 
receptor and to hydroxyapatite. 
dL Osteonectin
Osteonectin is the most abundant noncollagenous protein present in bone 
matrix. The molecule is an acidic glycoprotein of molecular weight 32kDa, it 
is rich in cysteine residues and contains several intramolecular disulphide 
bonds. The N terminal region is acidic with a clustering of negative charges 
and is a potential binding site for hydroxyapatite. The predicted amino acid 
sequence, determined by analysis of cDNA clones from several species, 
shows greater than 90% homology.
Osteonectin is secreted by a variety of connective tissue cell types and is 
present in skin and tendon. However, levels in bone are 1-10,000 times 
higher than in other connective tissues. Northern analysis of RNA extracted 
from tissues shows expression of osteonectin in bone, periodontal ligament 
and skin. Immunohistochemical studies demonstrate localisation of the 
protein to preosteoblasts, osteoblasts, newly deposited osteoid mineralised 
matrix and osteocytes (Young etal, 1990). Osteonectin is also expressed by 
cells of the expanding decidua of the placenta, indicating the predominance 
of the protein in tissues which are undergoing active remodelling.
Osteonectin is present in the a granules of platelets and is released as a 
complex with thombospondin during platelet aggregation. Platelet and bone 
osteonectin are structurally and immunologically different (Malaval et al, 
1991). The precise function of platelet osteonectin is not known but 
Clezardin eta l (1991) have demonstrated that antiosteonectin F(ab' ) 2 
fragments inhibit collagen-induced platelet aggregation in a dose- 
dependent manner. These authors postulate a role for osteonectin in the 
maintenance of platelet aggregation. Osteonectin is a potent inhibitor of 
crystal growth in vitro and was five times more potent than osteocalcin in
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this respect (Romberg etal, 1986). Osteonectin avidly binds collagen and 
has been reported to promote the deposition of calcium phosphate onto type 
I collagen in vitro and may play a role in mineralisation (Termine etal,
1981).
 gone  s ia lpprote in
Bone sialoprotein (BSP) is a glycoprotein of molecular weight 70,000- 
80,000Da and consists of 50% protein, 1 2% sialic acid, 7% glucosamine 
and 6 % galactosamine. BSP is synthesised as a pre-protein of 317 amino 
acids (34,982Da) which is processed to a 33,352Da protein before being 
made into the highly modified glycoprotein. The molecule contains no 
cysteine residues or disulphide bonds (Fisher etal, 1990).
In situ hybridisation of mRNA and immunostaining showed expression of 
BSP in osteoblasts, osteocytes and in some hypertrophic cartilage in 
developing human long bones and calvariae. A few osteoclasts also 
expressed the protein and BSP was localised to bone matrix (Bianco etal, 
1989). Like osteopontin, BSP has cell attachment activity and possesses an 
RGD seqence, however osteopontin is much more active at promoting cell 
attachment at lower concentrations (Somerman, Fisher and Foster, 1988). 
The presence of BSP has been demonstrated in platelets and the protein is 
released from thrombin-activated platelets (Chenu and Delmas, 1992). 
However, patients with gray platelet syndrome - a disorder characterised by 
a deficiency of platelet a granules - also demonstrated a release of BSP. 
Unlike osteonectin and thrombospondin which are released from the a 
granules, BSP would appear to be endocytosed from plasma by 
megakaryocytes. The levels of BSP in serum may reflect changes in bone 
remodelling.
f). Proteoglycans
Proteoglycans I (biglycan) and II (decorin) make up around 10% of the 
noncollagenous proteins present in bone matrix. These molecules possess
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a protein core to which there is covalent attachment of long chains of 
repeated disaccharide units, termed glycosaminoglycans. Proteoglycan I 
(Mr 350,000) contains two chondroitin sulphate chains and proteoglycan II 
(Mr 200,000) contains one chondroitin sulphate chain. N terminal sequence 
analysis revealed that the two are homologous yet distinct (Fisher et al,
1987). Proteoglycans are synthesised by human osteoblast-like cells in vitro 
(Beresford etai, 1987), but are not unique to bone. They are found in 
articular cartilage, nasal cartilage, skin, tendon, sclera, cornea, and aorta. In 
soft connective tissues they exist as dermatan sulphate proteoglycans, 
whereas in bone they bear chondroitin sulphate. In bone, biglycan and 
decorin are immunolocalised to matrix and cells in areas of new bone 
formation (Gehron Robey, 1989).
1.3 The maintenance of mineral homeostasis.
The adult human body contains approximately 1100g of calcium of which 
99% is stored in the skeleton in the form of hydroxyapatite which has the 
chemical formula Ca10(PO4 )6(OH)2 . 40% of total serum calcium (normally
2.5 mmol/L) is bound to protein, principally to albumin, and 10% is 
complexed with diffusible anions. 50% of serum calcium is ionised and 
maintenance of this fraction in the body fluids is essential for proper bone 
mineralisation, membrane integrity, cellular biochemical reactions, blood 
coagulation, muscle contraction, and nerve function. Phosphorous is 
essential for metabolic reactions that require energy which is supplied by 
adenosine triphosphate (ATP). Total body phosphorous is 500-800g and 
85-90% is found in the skeleton.
The hormones, vitamin D3 and PTH are the principal regulators of calcium 
metabolism. Vitamin D3 (cholecalciferol) is formed by ultraviolet radiation of 
the precursor molecule 7-dehydrocholesterol which is present in skin.
Vitamin D3 is metabolised in the liver by hydroxylation at carbon 25 to yield
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25-hydroxyvitamin D3, the major circulating form of vitamin D3 with a serum 
concentration of 25ng/ml and a half life of 15 days. Final metabolic 
conversion occurs in the kidney where hydroxylation at carbon 1 yields 1,25- 
dihydroxyvitamin D3. 1,25D has a circulating half-life of 15h and a plasma 
concentration of 20-50pg/ml. PTH is synthesised by chief cells of the 
parathyroid gland.
The regulation of calcium homeostasis is depicted in figure 1 .2 . Calcium 
ingested in the diet is actively transported out of the intestine and some 
absorption also occurs by passive diffusion. Active transport of both Ca2+ 
and PO43- is facilitated by 1,25D, the active metabolite of vitamin D3. The 
intestine is the principal target organ of 1.25D although the hormone also 
facilitates reabsorption of Ca2+ in the kidney. The formation of 1,25D is 
regulated in a feedback fashion by plasma Ca2+ and PO43- . High plasma 
PO43- levels directly inhibit renal 1 a-hydroxylase and levels of 1,25D fall in 
the presence of increased plasma calcium. When plasma Ca2+ is low, 
secretion of PTH from the parathyroid gland is increased. PTH increases the 
formation of 1,25D which in turn increases release of Ca2+ and PO43- from 
bone, restoring the plasma levels. PTH also mobilises calcium from bone, 
increases bone resorption, increases Ca2+ reabsorption in the kidney, and 
increases the excretion of phosphate ions.
1.4. The cells of bone
1.4.1 Lining cells.
In the adult, bone lining cells occupy the majority of bone surfaces 
considered inactive or resting because they are not being remodelled.
Lining cells are flattened cells immediately apposed to the bone surface and 
they generally contain few intracellular organelles. The role of lining cells is 
unknown but they may serve as nutritional support cells for osteocytes via 
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Fig. 1.2 The control of calcium homeostasis by parathyroid hormone and
1,25-dihydroxyvitamin D3 . PTH, secreted in response to low plasma 
calcium, increases Ca2+ reabsorption in the kidney, stimulates bone 
resorption, and enhances the activity of kidney a hydroxylase. 1,25- 
dihydroxyvitamin D3  increases intestinal absorption of Ca2+ and also 




The osteoblast is the bone-forming cell, it produces and secretes collagen 
and other noncollagenous proteins providing an organic matrix which is 
subsequently calcified. In histological sections of bone the osteoblast is 
recognised by its cuboidal shape and its position directly apposed to the 
bone surface. The osteoblast is a highly metabolically active cell and this is 
reflected in its ultrastructure. There is an extensive network of rough 
endoplasmic reticulum (RER) clustered in the cytosol nearest the bone 
surface. Between the nucleus and the RER is the Golgi apparatus. This 
structure is present because of the large amount of type I collagen 
synthesised and secreted by the cells. The cells also contain numerous 
mitochondria. At the bone surface, cytoplasmic processes extend from the 
osteoblast through the osteoid. These processes may serve as a 
communication link with osteocytes embedded in the matrix. The osteoblast 
is rich in the enzyme alkaline phosphatase. The precise function of this 
enzyme is not known. In the genetic disorder hypophosphatasia a 
deficiency of this enzyme occurs resulting in severe osteomalacia 
demonstrating that alkaline phosphatase is essential for skeletal 
mineralisation (Whyte etal, 1979).
Osteoblasts that are actively engaged in laying down matrix first synthesise 
type I collagen. The collagen matrix is subsequently ’decorated' with the 
noncollagenous proteins of bone. Mineralisation of the osteoid is also under 
the control of the osteoblast although the precise mechanism is not 
understood. Mineralisation of collagen occurs at the calcification front, the 
interface between osteoid and calcified bone. Hydroxy apatite crystals form 
in association with matrix fibrils that are collagen - noncollagenous protein 
complexes. More mineral appears at the gap regions that occur between 
collagen fibers.
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In addition to its bone forming activities, the osteoblast plays a major role in 
regulating osteoclastic bone resorption. The osteoblast possesses surface 
receptors for parathyroid hormone and nuclear receptors for 1,25D whereas 
the osteoclast does not (Kream etal, 1977). These two hormones are potent 
stimulators of bone resorption and their effects on resorption may be 
mediated by the osteoblast (McSheehy and Chambers, 1986; 1987). 
Osteoblasts also possess receptors for interleukin 1 (Bird and Saklatvala, 
1986), and oestrogen receptors (Eriksen eta l, 1987).
1.4.3 Osteocvtes
Osteoblasts that become embedded in the calcified extracellular matrix 
during bone formation are osteocytes, the end cells of the osteogenic 
lineage. Osteocytes have long cell processes which are in contact with 
previously incorporated osteocytes and osteoblasts at the surface of bone 
(Stanka, 1975; and Nijweide, van der Plas and Scherft, 1981), the 
cytoplasmic process lie in canals or canaliculi. The osteocyte lies within a 
lacuna filled with extracellular fluid. Deeper into the bone the osteocytes 
become smaller and lose many of their cytoplasmic organelles. Osteocytes 
do not divide but may secrete matrix at the surface of the lacuna, followed by 
calcification.
1.4.4 The osteoblast lineage
Marrow stromal tissue is a network of cells and extracellular matrix which 
physically supports the haemopoietic cells and influences their 
differentiation. When marrow fragments or marrow cell suspensions are 
implanted into diffusion chambers in vivo an osteogenic tissue of bone and 
cartilage is formed (Rosin, Freiburg and Zajicek, 1963; Friedenstein, 
Piatetzky-Shapiro and Petrakova, 1966). Cultures of marrow stromal 
fibroblasts are readily established in vitro from single-cell bone marrow 
suspensions and colonies derived from a single initiating colony-forming 
unit (CFU-F) can be obtained. CFU-F is capable of proliferating and
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differentiating into all the stromal cell lines necessary for the formation of 
bone and a haemopoietic microenvironment (reviewed by Owen, 1988; 
Beresford, 1989). CFU-F give rise to fibroblastic, adipocytic, reticular and 
osteogenic cell lines. As certain CFU-F are capable of forming a bone and 
marrow organ when grafted under the renal capsule in vivo, whereas some 
colonies produce bone only, it has been postulated that CFU-F contains 
both stromal stem cells and committed osteogenic precursors. The stages 
of osteoblastic differentiation, from a committed progenitor to the mature 
osteoblast, have not yet been elucidated owing to a lack of suitable 
biochemical or cell-surface markers.
1.4.5 Osteoclasts
The osteoclast is a highly differentiated, specialised, multinucleate cell that 
has the capacity to resorb bone. Osteoclasts are not observed on quiescent 
bone surfaces but seen at sites of actively remodeling bone, at the 
metaphysis of growing bones, or in pathological states. Such a distribution 
implies that osteoclasts are formed from precursors only as and when 
required. The regulation and mechanisms of osteoclast formation are poorly 
understood but local factors produced by osteoblasts can stimulate both the 
proliferation and differentiation of osteoclast progenitors.
The osteoclast is a giant cell formed by fusion of precursors. Osteoclasts 
contain around 10-20 nuclei which are centrally placed and contain 1-2 
nucleoli. An actively resorbing osteoclast contains many primary 
lysosomes, numerous mitochondria, a RER where lysosomal enzymes are 
synthesised, and prominant Golgi stacks. Osteoclasts are rich in the enzyme 
tartrate-resistant acid phosphatase (TRAP). Elevated plasma levels of TRAP 
are associated with increased bone turnover in metabolic bone diseases. 
Inhibition of TRAP activity by a specific antibody, or the specific phosphatase 
inhibitor molybdate, causes an inhibition of bone resorption (Zaidi etal, 
1989). TRAP is a pyrophosphatase and pyrophosphate is a potent inhibitor
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of apatite solubilisation, the first step in bone resorption. TRAP may serve to 
remove pyrophosphate in the early stages of resorption.
At the interface of the osteoclast and the bone the resorbing cell has a 
ruffled border where the plasma membrane has numerous folds and 
invaginations allowing intimate contact with the bone surface. The ruffled 
border is entirely surrounded by an annular zone rich in contractile proteins. 
This so-called sealing zone, where the plasma membrane is closely 
apposed to the bone surface, mediates attachment of the osteoclast to the 
bone matrix and seals off a resorption compartment. Resorption occurs at 
the ruffled border forming a pit or Howship's lacuna.
Bone is resorbed by the action of proteolytic enzymes which are 
transported via primary lysosomes and are secreted into the resorption 
lacuna. Baron et al (1985) have demonstrated that the plasma membrane of 
the ruffled border expresses a 100kDa lysosomal membrane protein. No 
expression of this protein was observed at the plasma membrane of the
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sealing zone or facing the bone marrow compartment. The 100kD protein is 
characteristic of the limiting membrane of secondary lysosomes and its 
distribution at the ruffled border suggests that the resorption lacuna functions 
as a secondary lysosome. The osteoclast is rich in the enzyme carbonic 
anhydrase II, an enzyme associated with acid-secreting epithelia, which 
generates hydrogen ions. H+ ions are pumped across the membrane of the 
ruffled border by a proton pump identical to the kidney H+ ATPase (Blair et 
al, 1989). The acidic microenvironment so formed is sufficient to dissolve 
the mineral phase of bone matrix and provides optimal conditions for the 
degradative action of acid hydrolases.
A further mechanism whereby osteoclasts may resorb bone is via the 
production of oxygen-derived free radicals. Generation of free radicals by 
injection of xanthine/xanthine oxidase over the calvariae of 5 week old mice 
caused bone resorption, characterised by an increase in osteoclast numbers
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and activity, which was inhibitable by superoxide dismutase (SOD) (Garrett 
etal, 1990). PTH and interleukin 1-induced resorption was also inhibited by 
SOD but not by catalase, indicating that peroxide anions and not hydroxyl 
anions were responsible for the resorptive effect. The generation of free 
radicals by osteoclasts was visualised with the dye nitroblue tetrazolium 
(NBT) and calcitonin decreased the number of NBT positive osteoclasts.
The generation of oxygen-derived free radicals by activated phagocytes and 
osteoclasts may be responsible for the bone resorption and tissue damage 
that occurs in chronic inflammatory conditions such as rheumatoid arthritis.
Gottesburen and co-workers, using polyclonal antibodies to bone matrix 
proteins, have shown the presence of osteocalcin, decorin and biglycan 
within cytoplasmic vesicles of the osteoclast (Gottesburen etal, 1991). In 
addition, workers in this laboratory raising monoclonal antibodies to primary 
cultures of human osteoblasts have demonstrated antibodies that bind to the 
cytoplasm of osteoclasts (S. Walsh, unpublished observations). These 
studies would suggest that as bone is resorbed matrix particles are engulfed 
by the osteoclast.
Osteoblasts in vitro have been shown to secrete plasminogen activator 
which can activate collagenase (Hamilton etal, 1984). It has been 
suggested that osteoblasts prepare the surface of the bone for osteoclastic 
resorption by degrading the non-mineralised layer of collagen and thereby 
exposing the mineralised matrix for attack by the osteoclast (Chambers,
1988). However, scanning EM studies show that osteoclasts do not require 
preparation by osteoblasts for resorption to occur and isolated osteoclasts 
can resorb bone without the apparent support of other cells (Boyde et al, 
1986).
1.4.6 The osteoclast lineage
Osteoclasts are thought to be derived from haemopoietic precursors in the 
bone marrow (Mundy, 1990). Evidence suggests that the osteoclast is
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derived from a colony forming unit for the granulocyte-macrophage series 
(CFU-GM), which can give rise to osteoclast precursors, monocytes and 
granulocytes. Mononuclear precursors, which proliferate, differentiate, and 
fuse to form the mature osteoclasts, respond to colony stimulating factors 
which act only on cells derived from CFU-GM (Mundy, 1990). In addition, 
monocytes and macrophages have been shown to degrade devitalised 
bone (Mundy et al, 1977). However, other workers report that osteoclasts 
do not express common leucocyte antigen or monocyte markers (Horton et 
al, 1985). The true ontogeny of the osteoclast is as yet uncharacterised.
1*5 The bone remodeling cvcle
Throughout life the skeleton is constantly remodelled disynchronously at 
numerous sites. Bone remodelling maintains mineral homeostasis and 
serves to resorb effete bone replacing it with new matrix (Parfitt, 1984). The 
activities of osteoblasts and osteoclasts are tightly coupled and since bone 
remodelling occurs regardless of the endocrine status of the individual it is 
likely that locally produced growth factors play the major role in this coupling 
process. The process of bone remodelling can be described as a series of 
events (Baron, Vignery and Horowitz, 1983), depicted in figure 1.3.
Bone that is not being actively remodelled is in a state of quiescence. 
Osteoclasts are not seen and the cells lining the surface of the bone are 
flattened and apparently in a resting state. The first stage of the cycle is 
activation; mononuclear cells are recruited to the bone surface and 
osteoblasts that were lining the bone surface stop synthesising matrix and 
become flattened. The activated mononuclear cells reach the bone surface 
by sending long pseudopods between the now flat lining cells. The plasma 
membranes of the mononuclear cells become ruffled along the bone 
surface. The cells fuse to form multinucleate giant cells with ruffled borders 
and tight sealing zones, and begin to resorb bone.
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Bone resorption involves the removal of both mineral and organic 
constituents of bone and occurs in areas where osteoclasts are attached to 
the bone surface. During the resorptive phase osteoclasts resorb a quantum 
of bone, forming a Howship's lacuna.
Reversal follows the resorption phase. The osteoclasts are replaced by 
large phagocytic cells that may be fission products of the osteoclasts.
During reversal a "cement line" is laid down which contains glycoproteins, 
glycosaminoglycans and acid phosphatase. The cement layer components 
may be chemoattractants for osteoblasts which colonise the Howship's 
lacuna. Mundy e ta l(1982) have demonstrated that conditioned media from 
resorbing bone cultures are chemotactic for osteoblast-like osteosarcoma 
cells. Factors released during resorption may thus recruit osteoblast 
precursors to the remodelling site. Reversal is followed by a new round of 
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Fig.1.3 The cellular events of the bone remodeling cycle.
l i£  Systemic and local factors affecting bone remodeling.
In the bone microenvironment bone cells are in intimate association with 
both neighbouring cells and the osteoid matrix; signals from a whole 
plethora of systemic hormones, local factors, cytokines and adhesion 
molecules regulate the resorption of effete bone and its subsequent 
renewal. The characteristics and actions of some of the major factors are 
described below. The effects of cytokines interleukin 1 , interleukin 6  and 
tumour necrosis factor a on human osteoblast-like cells are more fully 
described in Chapter 5 of this thesis.
1 .6.1 Systemic factors 
aL Parathyroid hormone
PTH is an 84 amino acid peptide synthesised by chief cells of the 
parathyroid gland. The hormone is synthesised as part of a larger precursor 
molecule containing a 25 amino acid hydrophobic residue-rich signal 
sequence and a 6  amino acid prosequence. These portions of the precursor 
are sequentially removed within the cell and 84 amino acid PTH is released 
from storage granules. After secretion PTH is cleaved between residues 33 
and 34. The amino terminal fragment has the full biological activity of the 
intact molecule, the carboxy-terminal fragment is inactive. The synthesis 
and secretion of PTH are regulated by serum Ca2+ and PTH is essential to 
the maintenance of serum calcium concentrations. Bone and kidney are the 
two principal target organs of PTH. Cell surface receptors for PTH are 
coupled to adenyl cyclase and cAMP is the intracellular mediator of PTH 
action.
PTH stimulates bone resorption in organ cultures and increases the 
number and activity of osteoclasts (Holtrop and Raisz, 1979). McSheehy 
and Chambers (1986) report that PTH had little effect on isolated 
osteoclasts, the bone resorptive effect of PTH required the presence of 
accessory cells such as osteoblasts. PTH stimulates the fusion of osteoclast
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precursors but as this can occur in the presence of DNA synthesis inhibitors 
this effect is apparently not dependent on proliferation of the precursors 
(Lorenzo, Raisz and Hock, 1983).
PTH stimulates the production of cAMP in osteoblasts, however cyclic 
nucleotide analogues which block the PTH stimulation of cAMP do not 
inhibit bone resorption. In addition, PTH analogues which have little effect 
on cAMP can stimulate bone resorption suggesting that other messengers 
are involved (Raisz, 1988a). PTH has also been reported to have anabolic 
effects in bone; Tam eta l (1982) report that PTH stimulates the bone 
apposition rate in thyroparathyroidectomised rats. Intermittent doses of PTH 
stimulated the rate of mineralised matrix production at individual formation 
loci. Endo et al (1980) observed an enhancement of calcification of osteoid 
matrix in chick embryonic femur treated with PTH and 3 vitamin D3 
metabolites in organ cultures in vitro. Conversely, PTH inhibits collagen 
synthesis in the rat osteosarcoma cell line ROS 17/2. The anabolic effects of 
PTH may be due to an increase in osteoblast cell number as the hormone 
stimulates proliferation of human trabecular bone cells (MacDonald et al, 
1984).
 1.25-dihvdroxvvitamin Da
1,25D binds with high specificity and affinity to an intracellular receptor 
protein present in bone (Kream etal, 1977). 1,25D is a potent stimulator of 
bone resorption (Raisz etal, 1972) and stimulates formation and activity of 
multinucleate giant cells in long term human bone marrow cultures 
(Roodman etal, 1985). 1,25D stimulated the alkaline phosphatase (ALP) 
activity of rat osteogenic sarcoma cells (ROS 17/2) in a dose dependent 
manner and inhibited cell growth (Manolagos, Burton and Deftos, 1981).
The hormone also enhanced ALP activity in two human osteogenic 
osteosarcoma cell lines, SAOS and TE85 (Mulkins etal, 1982) and
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enhanced ALP activity and inhibited growth in human trabecular bone 
derived cells (Beresford, Gallagher and Russell, 1986).
1,25D has been reported to specifically enhance synthesis of type I 
collagen in the human osteosarcoma cell line MG-63 (Franceschi, Romano 
and Park, 1988) and in human osteoblast-like cells (Beresford, Gallagher 
and Russell, 1986). However, 1.25D inhibited collagen synthesis in ROS 
17/2 cells (Kream etal, 1986). 1,25D stimulates the production of 
osteocalcin by human osteoblast-like cells (Beresford etal, 1984) and 
regulates the production of other bone matrix proteins (Gehron Robeijetal, 
1986).
Vitamin D3 may also influence cells of the immune system. Monocytes and 
activated T cells possess receptors for 1,25D (Peacock et al, 1982). 1,25D 
inhibits T cell proliferation and production of IL-2 (Rigby, Stacy and Fanger, 
1984), and can enhance expression of interleukin 1 (IL-1) in monocytes 
(Bhalla, Amento and Krane, 1986). Activated macrophages from the 
synovial fluid of patients with inflammatory arthritis can convert 25- 
hydroxy vitamin D3 (25-(OH)D) to the active metabolite 1,25D, and these 
patients respond to a 25-(OH)D challenge with an increase in serum 
concentration of 1,25D (Mawer et al, 1991). Mononuclear cells at the 
surface of bone may respond to 1,25D by enhanced production of 
interleukin 1 (IL-1), thus contributing to local bone remodelling. Extrarenal 
production of 1,25D in pathological conditions such as arthritis may 
contribute to bone loss by directly; enhancing bone resorptioifand via 
stimulation of the potent resorbing agent IL-1.
Gl Calcitonin
Calcitonin is a 32 amino acid polypeptide synthesised by neuroendocrine 
cells located within the thyroid gland. The hormone is synthesised as a 
portion of a larger precursor protein. Circulating levels of calcitonin are 
<1 0 0 pg/ml and its half-life is 10 minutes. The synthesis and secretion of
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calcitonin are controlled by the concentration of serum ionised Ca2+. An 
increase in serum Ca2+ suppresses PTH secretion and the synthesis of 
calcitonin is increased. Calcitonin decreases bone resorption by inhibiting 
osteoclast function, resulting in lowered serum Ca2+ and PO42' 
concentrations. Calcitonin increases urinary excretion of Ca2+, PO42-, K+, 
Na2+, and Mg2+ but this effect persists only as calcitonin concentrations 
remain elevated.
The physiological effects of calcitonin on serum Ca2+ in humans are minor. 
The effects of this hormone are most marked when rates of bone turnover 
and osteoclastic activity are highest as in the young or in Paget's disease. 
Administration of calcitonin reduces accelerated bone turnover in Paget's 
disease of bone.
dL Oestrogen
The dramatic reduction of circulating oestrogen levels following the 
menopause is thought to be a major factor affecting the onset of 
osteoporosis, a disease characterised by increased bone turnover and 
trabecular bone loss (Raisz, 1988b). At the menopause there is an increase 
in bone resorption accompanied by a smaller increase in bone formation so 
that bone mass decreases. Reduction of bone mass causes an increased 
susceptibility to fractures. Treatment with oestrogen, as hormone 
replacement therapy, leads to an overall gain in bone mass. This would 
suggest a role for oestrogen in maintaining normal bone mass via anabolic 
effects on osteoblasts.
Ernst, Schmid and Froesch (1988) describe the effects of 17p-oestradiol 
(E2 ) on osteoblast-like cells cultured from neonatal rat calvariae. Using this 
model, oestradiol stimulated proliferation of the cells and increased steady- 
state levels of mRNA for the a1 chain of type I procollagen. The effect of 
oestrogen was inhibitable by tamoxifen, an agent that competes with E2 for 
binding to the receptor, and no effect was observed with the stereoisomer
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17a-oestradiol. In further studies Ernst, Heath and Rodan (1989) report that 
E2 enhanced the proliferation of osteoblasts derived from rat long bones and 
of the Simian Virus 40 (SV40) immortalised rat osteoblast-like cell lines 
RCT-1 and RCT-3. Alkaline phosphatase activity was not affected by E2 in 
these cells. E2 decreased PTH responsive cAMP in both these cell types 
and enhanced mRNA levels for insulin-like growth factor I (IGF-I). When 
cultures of primary rat calvarial osteoblasts were exposed to E2 with a 
monoclonal directed against IGF-I, the E2 induced proliferation was 
inhibited.
Further evidence of a role for IGFs in mediating the effects of oestrogen is 
supplied by Gray e ta l(1989). These workers report an increase in the 
production of both IGF-I and II stimulated by E2 in the rat osteosarcoma cell 
line UMR106. 1,25D also enhanced production of IGF-I but pretreatment 
with E2 blocked this response.
Egrise et al {1990) studying cultured osteoblasts from mature female rats 
observed a decrease in 3H-thymidine incorporation in response to E2 . E2 
enhanced alkaline phosphatase activity in these cells, but decreased the 
osteocalcin produced in response to 1,25D. Such differences in 
responsiveness of different model systems may reflect different stages of 
differentiation represented by these cultures. The small effects observed 
with oestradiol may be due to a subpopulation of cells displaying oestrogen 
responsiveness.
Keeting et al (1991b) studied the effects of 17p-oestradiol on primary 
cultures of human osteoblasts derived from trabecular bone. These workers 
report no direct effects of E2 on either proliferation or differentiation of adult 
human osteoblasts. No interaction of E2 with insulin, 1,25D or 
dexamethasone was observed. Oestradiol displayed equivocal effects on 
mRNA for pro-a (l)-collagen, increasing steady state levels in 6/11 cell
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strains, having no effect in 3 cell strains and decreasing the mRNA levels in 
2  cell strains.
Specific binding sites for oestrogen have been demonstrated in ROS 
17/2.8 rat osteosarcoma cells and in the human osteosarcoma line HOS 
TE85 (Komm etal, 1988). The number of high affinity binding sites per cell 
was low (~ 2 0 0  detectable) compared to uterus which possesses several 
thousand high-affinity oestrogen receptors per cell. The low number of 
receptors present in the osteoblast-like cells were sufficient to elicit a 
response to oestrogen. The hormone increased mRNA for type I 
procollagen by 2 fold and enhanced mRNA for TGF-p by 2.5 fold in the cell 
lines studied. Oestrogen receptors have also been demonstrated on 
primary cultures of human osteoblasts (Eriksen eta l, 1988).
The precise role of oestrogen in the regulation of bone metabolism 
remains unclear. Riggs e ta l(1972) describe the effects of oestrogen 
therapy in postmenopausal osteoporotic subjects. Treatment decreased the 
values for bone resorbing surfaces as determined by microradiography of 
iliac crest biopsies. Long-term treatment however resulted in a secondary 
decrease in bone formation. The principal effect of oestrogen therapy may 
be a decrease in the progression of bone loss.
1.6.2 Locally derived factors 
aV Interleukin 1
In 1972, Horton eta l described bone resorbing activity in conditioned 
medium from human peripheral blood mononuclear cells. This so-called 
Osteoclast Activating Factor (OAF) has since been demonstrated to be due 
to a variety of cytokines, including interleukin 1. IL-1 is a potent stimulator of 
bone resorption both in vivo (Sabatini etal, 1988) and in vitro (Gowen etal, 
1983; Gowen and Mundy, 1986; Stashenko etal, 1987). IL-1 stimulates the 
proliferation of osteoclast precursors and their fusion to form multinucleate 
giant cells in human long term bone marrow cultures (Pfeilschifter etal,
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1989). IL-1 stimulates the production of prostaglandin E2 (PGE2) which in 
turn is a potent stimulator of bone resorption (Gowen, 1988). IL-1 failed to 
stimulate resorption by isolated rat osteoclasts maintained on slices of 
human cortical bone; the presence of calvarial osteoblasts as accessory 
cells was necessary for the resorptive effect of IL-1 (Thomson, Saklatvala 
and Chambers, 1986).
Interleukin 1a (IL-1 a) and IL-1 p are acidic and neutral products of two 
separate genes with limited homology in their primary structures but 
apparently identical bioactivities. Both proteins have a molecular weight of 
17kDa and are derived by complex proteolytic cleavage from larger 
precursors. Interleukin 1 is produced by peripheral blood monocytes and 
tissue macrophages; it induces fever and the acute phase response, 
enhances lymphocyte proliferation and stimulates haemopoiesis. IL-1 can 
stimulate synovial cells, chondrocytes and fibroblasts to secrete proteinases 
such as collagenase and plasminogen activators thus contributing to 
connective tissue breakdown (Gowen, 1992).
IL-1 may also have anabolic effects on bone by stimulating the proliferation 
of osteoblasts (Gowen, Wood and Russell, 1985; Evans, Bunning and 
Russell, 1990). However, IL-1 antagonises 1,25D induced osteocalcin 
synthesis by human osteoblast-like cells and inhibits alkaline phosphatase 
expression in these cells (Evans, Bunning and Russell, 1990). IL-1 in low 
doses inhibits collagen synthesis whereas high doses or prolonged 
exposure stimulate collagen synthesis (Canalis, 1986).
In a study by Pacifici eta l (1987), monocytes from the peripheral blood of 
patients with osteoporosis were shown to have significantly higher levels of 
IL-1 than monocytes from normal subjects. Patients whose monocytes 
secreted high levels of IL-1 also had a higher rate of bone formation. A 
marked increase in blood monocyte IL-1 production was observed following 
the menopause and this increase was suppressed by ovarian steroid
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therapy (Pacifici etal, 1989). Increased IL-1 activity may reflect the rapid 
bone turnover that occurs after the menopause, and may play a role in the 
pathogenesis of postmenopausal osteoporosis.
Bone matrix constituents released during bone resorption may stimulate 
IL-1 release from blood mononuclear cells. Pacifici et a /(1991) 
demonstrated the ability of bone fragments, collagen, and hydroxyapatite to 
stimulate IL-1 release from peripheral blood mononuclear cells. In this way, 
IL-1 could initiate a cascade of events that leads to further production of IL-1 
and to an amplification of bone resorption (Figure 1.4). 1,25D may further 
potentiate this effect by enhancing IL-1 production by monocytes (Bhalla, 
Amento and Krane, 1986). IL-1 may be a potent mediator of bone loss in 
conditions of chronic inflammation. 
bL Tumour necrosis factor
Tumour necrosis factor (TNF) was originally identified on the basis of its 
ability to cause haemorrhagic necrosis of tumours in patients with bacterial 
infections. A separate activity called cachectin, responsible for tissue 
wastage and weight loss in tumour-bearing animals, was subsequently 
shown to be identical to TN F (Beutler and Cerami, 1987). Cachectin is an 
endogenous pyrogen, capable of inducing fever both by a direct effect on 
hypothalamic neurones and by induction of IL-1. TN F exists as two proteins, 
T N F a and TNFp, which share approximately 30% amino acid homology and 
have a similar spectrum of activity. TN Fa is released by activated 
macrophages whereas TNFp (lymphotoxin) is lymphocyte-derived.
Bertolini etal, (1986) demonstrated that both TN Fa and lymphotoxin (LT) 
stimulate bone resorption in a dose-dependent manner in foetal rat bones 
and cause an increase in the number of multi nucleated osteoclasts. The 
resorptive effect of both cytokines was inhibited by calcitonin, demonstrating 
the involvement of osteoclasts. TN Fa and p inhibited the percentage
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Fig.1.4 Interleukin 1 and bone resorption. IL-1 is a potent stimulator of 
bone resorption and stimulates the release of other potent resorbing agents 
(e.g. TNF, PGE2) from osteoblasts . The subsequent release of bone 
fragments may further augment IL-1 production. 1,25D also increases 
production of IL-1 by monocytes, enhancing the resorptive signal.
LIF - Leukaemia Inhibitory Factor
PBMC - Peripheral blood mononuclear cells
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collagen synthesis of foetal rat bone explants, and also inhibited alkaline 
phosphatase expression in the rat osteogenic sarcoma cell line ROS 17/2.8. 
The resorptive effect of the TNFs is 1,000 fold less potent than IL-1. 
Suboptimal concentrations of TNF and lymphotoxin produce a synergystic 
effect when co-incubated with suboptimal concentrations of IL-1, resulting in 
a twofold increase in activity of IL-1 and a 100 fold increase in the resorptive 
activity of TNF and LT (Stashenko et al, 1987). TNF also causes the release 
of proteoglycan from cartilage and inhibits formation of new cartilage by 
inhibiting proteoglycan production (Saklatvala, 1986).
The precise mechanism of TN F and LT induced bone resorption is 
unknown. Thomson, Mundy and Chambers (1987) demonstrated that 
isolated osteoclasts incubated with TN Fa and p failed to respond to the 
cytokines by enhanced resorption of cortical bone unless calvarial 
osteoblasts were also present. These data would suggest that osteoblasts 
mediate the effect of TN F by producing a resorbing factor. However, such a 
factor has not yet been identified. The heterogeneous populations of cells 
used by these authors would not permit identification of the specific cell 
types responding to resorptive agents.
Transient (24h) treatment with TN Fa caused an increase in DNA synthesis 
in cultured rat calvariae, an increase in alkaline phosphatase, and an 
increase in 3H-proline incorporation which was DNA synthesis dependent 
(Canalis, 1987). Continuous treatment of the calvariae (48-96h) with TN F  
caused an inhibition of collagen synthesis and an inhibition of alkaline 
phosphatase activity. TN Fa stimulates the proliferation of primary cultures of 
human osteoblasts (Gowen,1992). In the course of bone remodelling, TN F  
may enhance the proliferation of newly recruited osteoblast precursors prior 
to the deposition of new matrix.
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QL Interleukin 6
Interleukin 6  (IL-6 ) was originally characterised by several laboratories 
owing to its many actions on a wide variety of cell types. IL-6  has been 
designated as B-cell differentiation factor due to its ability to induce terminal 
differentiation of B cells into immunoglobulin secreting cells (Hirano et al, 
1986). IL-6  induces the differentiation of thymocytes and splenic T cells 
(Lotz et al, 1988) and is a potent growth factor for hybridoma cells (Aarden et 
al, 1987). IL-6  has strikingly similar activities to IL-1, notably induction of 
acute phase proteins in hepatocytes (Gauldie eta l 1987) and induction of 
fever (Helle eta l 1988). IL-6  is a glycoprotein of 184 amino acids derived 
by removal of an N-terminal hydrophobic leader peptide from a 2 1 2  amino 
acid precursor. IL-6  is produced by stimulated monocytes, endothelial cells 
and fibroblasts.
Conflicting results have been reported as to whether IL-6  induces bone 
resorption. Lowik eta l (1989) and Ishimi eta l (1990) report that IL-6  
induced bone resorption in foetal rat metacarpals and foetal mouse 
calvariae respectively. However, Al-Humidan eta l (1991) failed to observe 
a resorptive effect of IL-6  in neonatal mouse calvariae, in this study IL-6  had 
no effect on the bone resorption induced by IL-1 but inhibited both PTH and 
1,25D induced resorption. Such differences may be due to the different 
stages of differentiation displayed by these organ culture models. Addition 
of IL-6  to 17day-old foetal mouse metacarpals caused a dose-dependent 
increase in 45Ca release but had no effect on 17-day-old radii (Lowik, 1992). 
17day-old foetal mouse radii have a mineralised matrix that contains mature 
resorbing osteoclasts, metacarpals from the same animals possess a 
mineralised matrix that does not contain mature osteoclasts. IL-6  may act by 
enhancing the differentiation of haemopoietic precursors of osteoclasts, but 
may have no effect on the mature osteoclast.
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Primary rat osteoblast-like cells and the rat osteogenic sarcoma cell lines 
UMR-106 and ROS 17/2.8 constitutively produce IL-6  and this production is 
enhanced by PTH (Lowik, 1992; Littlewood etal, 1991b). It has been 
postulated that PTH may induce bone resorption by stimulating the 
production of IL-6  by osteoblasts. However, Garrett, Black and Mundy 
(1990) report no effect of IL-6  neutralising antibodies on PTH or 1,25D 
stimulated resorption in neonatal mouse calvariae, whereas the antibody 
inhibited the resorptive effect of IL-1 and TNF. Furthermore, human 
osteoblast-like cells failed to respond to PTH by enhanced IL-6  production 
(Littlewood etal, 1991b).
Patients with rheumatoid arthritis (RA) and other inflammatory arthritides 
were found to have significantly more IL-6  in synovial fluid than patients with 
osteoarthritis (Houssiau etal, 1988). IL-6  activity was detected in the serum 
of patients with rheumatoid arthritis but not in normal controls; in patients 
with RA IL-6  levels correlated with values for the acute phase protein C- 
reactive protein. In conditions of chronic inflammation IL-6  is clearly 
involved as an inducer of the acute phase response, a role for IL-6  in the 
joint destruction associated with RA is less clear. 
dL Transforming Growth Factor B
Transforming growth factor p (TGF-P), a 25kDa homodimeric peptide 
originally purified from human platelets, derives its name from its ability to 
induce anchorage - independent growth in non-neoplastic rat kidney 
fibroblasts (Pircher, Lawrence and Jullien, 1984). TGF-p has been isolated 
from a variety of normal and neoplastic cells, and bone is the most abundant 
source of TGF-p after platelets (Sporn etal, 1987).
Two distinct forms of TGF-p were identified first in bovine bone. These 
proteins were described as cartilage inducing factors A and B (CIF-A and 
CIF-B) due to their ability to induce the formation of cartilage proteoglycan 
and type II collagen in undifferentiated mesenchymal cells in vitro (Seyedin
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et al, 1985). CIF-A was found to be equivalent to the form of TGF-p purified 
from platelets, that is TGF-pi, and CIF-B is the same as TGF-P2. TGF-p is 
produced by fibroblasts, mesothelial cells, osteoblasts and transformed cells 
and is an important regulator of growth and differentiation. High affinity 
receptors for TGF-p have been identified in almost every cell type studied 
(Wakefield etal, 1987) and TGF-p has dramatic effects on cells possessing 
the receptor.
TGF-p appears to be an important immunosuppressive agent. B 
lymphocytes possess high affinity receptors for TGF-p and the protein 
suppresses factor-dependent IL-2 B cell proliferation and immunoglobulin 
secretion (Kehrl etal, 1986). B lymphocytes also synthesise and secrete 
TGF-p. TGF-p inhibits the proliferation of mitogenically stimulated T 
lymphocytes and also suppresses the proliferation of aja^humber of human 
tumour cell lines. TGF-p may also exert its actions as a potent inhibitor of 
cell growth, particularly on epithelial cells and mesenchymal cells such as 
embryonic fibroblasts. (Reviewed by Sporn etal, 1987).
TGF-p is secreted by virtually all cell types in a latent form. Latent TGF-p 
can be activated by transient acidification, by incubation with cathepsin D 
and by plasmin. Latent TGF-p fails to bind to the TGF-p receptor suggesting 
that extracellular activation of the molecule is essential for its actions 
(Wakefield etal, 1987). The necessity for extracellular activation of the 
molecule may be important in regulating the actions of TGF-p, which are so 
wide ranging. Little is known about the cellular activation of TGF-p.
TGF-p is produced by bovine bone cells and the osteoblast-like cell lines 
ROS 17/2.8 and UMR-106 (Gehron Robey etal, 1987) and has growth 
inhibitory or stimulatory activities depending on the osteoblast model 
studied. TGF-p increases type I collagen expression and decreases alkaline 
phosphatase activity in both fibroblastic and osteoblastic populations of 
foetal rat calvarial digests. TGF-p decreases cellular proliferation, and
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increases collagen and alkaline phosphatase expression in ROS 17/2.8 
cells, UMR-106 cells and in the human osteosarcoma cell line MG-63. 
However, TGF-p decreases alkaline phosphatase in the murine clonal 
osteoblast-like cell line MC3T3-E1 and in the human osteosarcoma cell line 
SaOS2 . TGF-p stimulates bone resorption in neonatal mouse calvariae via 
the synthesis of prostaglandins (Tashjian etal, 1985). TGF-p inhibits bone 
resorption in foetal rat long bone cultures (Pfeilschifter, Seyedin and Mundy,
1988) and inhibits the resorption induced by IL-1 and 1,25D in this model. 
TGF-p inhibited DNA synthesis in a similar manner to hydroxyurea in rat 
long bone cultures but neither TGF-p or hydroxyurea affect PTH induced 
resorption. The suppressive action of TGF-p on resorption in these cultures 
may have been due to an inhibition of osteoclast precursor proliferation. For 
a review of the actions of TGF-p on bone cells see Bonewald and Mundy 
(1989).
TGF-p is a potent osteoinductive factor in vivo. In soft tissues TGF-p 
accelerates healing of dermal wounds. Single applications of TGF-01 were 
sufficient to induce bone formation and complete healing in skull defects in 
rats (Beck etal, 1991b). TGF-p also induced bone formation in rabbit ear full 
thickness wounds; the early phase of formation was observed overlying the 
intact cartilage (Beck etal, 1991a). In both these studies TGF-p appeared to 
stimulate bone formation without a cartilagenous precursor. The bone 
formed was characterised by a mineralised matrix interspersed with marrow 
cavities that contained blood vessels. In rabbit ear full thickness wounds, 
no bone formation occurred if the perichondrium was left intact, suggesting 
that disruption of the perichondrium exposes chondroblasts and 
mesenchymal cells to the osteoinductive actions of TGF-p. TGF-p increases 
the synthesis of type II collagen in bovine periosteal cells but decreases ALP 
mRNA suggesting that the factor may promote chondrogenesis during 
fracture repair thus aiding fracture healing (Izumi etal, 1992).
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TGF-p is released from cells as an inert complex bound to one or more 
binding proteins which mask its biological activity. The TGF-p in bone 
culture media is in an inactive form. Isolated avian osteoclasts, stimulated to 
resorb by vitamin A, activate latent TGF-p (Oreffo etal, 1989). The area 
resorbed by the osteoclast (Howship's lacuna) under the ruffled border has 
a low pH which may be sufficient to activate latent TGF-p. Thus TGF-p is a 
likely candidate for the coupling of bone resorption and formation phases. 
TGF-p released as a result of resorption, and activated in the acidic 
environment of the resorption pit, may recruit osteoblast precursors to the 
resorption site and stimulate bone formation. 
e l Leukaemia Inhibitory Factor
A novel cytokine, leukaemia inhibitory factor (LIF) was purified from Krebs 
II ascites cell-conditioned medium, following the observation that the factor 
induced macrophage differentiation of the murine Ml myeloid leukaemia cell 
line (Hilton eta l, 1988). Moreau et a /(1988) subsequently isolated a cDNA 
clone encoding a novel human haemopoietic growth factor called human 
interleukin for DA cells or HILDA. This factor supports the proliferation of the 
interleukin 3 dependent murine leukaemic cell line DA-1 a. HILDA is 
produced by lectin stimulated C10-MJ2 T cells and both lectin and phorbol 
myristate acetate (PMA) stimulate the expression of mRNA for HILDA. The 
cDNA for HILDA encodes a 202 amino acid protein that is essentially 
identical to LIF (Moreau eta l 1988). Recombinant LIF/HILDA secreted by 
COS-1 cells is a glycoprotein of Mr 40,000.
A third factor, differentiation inhibitory activity (DIA) was purified from the 
medium conditioned by Buffalo rat liver (BRL) cells (Smith etal, 1988). This 
factor suppressed the spontaneous differentiation of murine embyronic stem 
(ES) cells, thereby maintaining the pluripotentiality of these cells in vitro . 
Purified DIA was found to be related in structure and function to LIF/HILDA. 
DIA purified from BRL cell conditioned medium is a single chain glycoprotein
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Mr 43,000 consisting of an extensively glycosylated central protein core of 
Mr 20,000. ES cells, in the absence of DIA, spontaneously differentiate and 
show an altered morphology. Incubation with DIA inhibited this 
differentiation. Purified recombinant LIF was shown to have a similar effect 
(Williams etal, 1988), and to substitute for DIA in the maintenance of 
totipotent ES cells. DIA, LIF and HILDA are multifunctional, regulatory 
molecules with both growth promoting or differentiation inducing activities, 
depending on the target cell type. The presence of receptors for LIF on ES 
cells was demonstrated by the binding of 125l labelled LIF, which was 
inhibited by DIA (Smith etal, 1988).
Evidence of a role for LIF in the regulation of bone turnover was suggested 
by the observation that LIF promoted bone resorption in a prostaglandin 
mediated manner in neonatal mouse calvariae (Abe eta l, 1986). In contrast, 
Metcalf and Gearing (1989) demonstrated a potent effect of LIF on bone 
formation in mice injected with cells producing high levels of the cytokine. 
The mice exhibited ectopic calcification in muscle tissue and liver and a fatal 
cachexia developed. Tumour necrosis factor is the only agent previously 
shown to induce cachexia (Rosenblum and Donato, 1989). LIF may be an 
equally potent agent or may act via the induction of TNF.
The presence of receptors for LIF in osteoblasts, but not in osteoclasts, was 
demonstrated by specific binding of 125I-LIF (Allan eta l, 1990). Osteoblasts 
obtained by digestion of rat calvariae, and the rat osteosarcoma cell line 
UMR106-06, produced LIF when treated with retinoic acid or TGF-a. LIF 
mRNA was detected in TGF-a treated UMR-201 cells, and was detected in 
unstimulated cells following polymerase chain reaction amplification of DNA 
copies of LIF transcripts. The rat osteoblasts responded to exogenous LIF 
by an increase in the mRNA and protein production of plasminogen activator 
inhibitor. LIF inhibited plasminogen activator induced by parathyroid 
hormone, 1,25D, PGE2, TNFa and TNFp.
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LIF has been reported to stimulate proliferation of osteoblasts obtained by 
digestion of rat calvariae. However, LIF decreased proliferation in the 
transformed osteosarcoma cell line UMR-106 (Lowe etal, 1991). LIF also 
suppresses proliferation in the murine clonal cell line MC3T3-E1 (Noda etal, 
1990), and inhibits platelet derived growth factor (PDGF) and IGF-I induced 
proliferation in these cells. LIF production is increased by TGF-p and TGF-a 
in murine and rat osteoblast-like cells (Marusic, Kalinowski and Lorenzo,
1990). LIF suppressed ALP activity, and mRNA for type I collagen in 
MC3T3-E1 cells, but enhanced osteopontin mRNA (Noda etal, 1990).
LIF may be an important paracrine factor in the local control of bone 
remodelling. LIF produced by osteoblasts in response to other cytokines 
(IL-1 and TNF) may act to increase bone resorption by enhancing the 
proliferation of osteoclast precursors. It is unlikely that LIF is the mediator 
responsible for the resorptive actions of PTH and 1,25D as both these 
hormones failed to stimulate LIF production by human osteoblast-like cells 
(Evans et al, 1990). The anabolic actions of LIF in vivo are consistent with 
the effects of this cytokine as an enhancer of DNA synthesis in osteoblasts. 
The inhibition of plasminogen activator by LIF would potentiate the anabolic 
actions of this cytokine.
The variation in responses of different populations of osteoblasts to LIF 
possibly reflects the heterogeneity of the cultures, and their different stages 
of differentiation. LIF has growth stimulatory or differentiation inducing 
activities depending on the target cell type. The inhibition of osteosarcoma 
cell lines by LIF may be a function of the transformed nature of these cells.
In the context of bone remodelling, LIF may act as both a growth promoter 
and an inducer of differentiation at different stages of bone formation and 
resorption. LIF may regulate bone cell function by acting in concert with 
other growth factors that are produced by osteoblasts or released from the 
matrix by resorbing osteoclasts.
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ft. Prostaglandins
Prostaglandins are 2 0 -carbon unsaturated fatty acids containing a 
cyclopentane ring. The essential fatty acid arachidonic acid is released from 
the 2 -position of plasma membrane phospholipids by the action of 
phospholipase A2, and serves as a substrate for the synthesis of 
prostanoids and leukotrienes. Prostanoid synthesis involves the 
consumption of two molecules of oxygen catalysed by prostaglandin 
endoperoxide synthase, an enzyme with cyclooxygenase and peroxidase 
activities. The product of the cyclooxygenase pathway, an endoperoxide 
(PGH), is converted to prostaglandins D, E and F as well as to the 
thromboxane TXA2 and prostacyclin (PGT2). Leukotrienes are synthesised 
by the action of the enzyme lipoxygenase on arachidonate.
The prostaglandins are potent biologically active substances and exist in 
virtually every mammalian tissue. Prostaglandins cause contraction of 
smooth muscle, aggregation of platelets, and are important inflammatory 
mediators. The synthesis of the eicosanoids can be inhibited by the action 
of anti-inflammatory corticosteroid hormones which stimulate the production 
of lipocortins which in turn inhibit the activity of phospolipase A2. Non 
steroidal anti-inflammatory agents such as aspirin and indomethacin block 
the activity of cyclooxygenase thus inhibiting the production of group 2  
prostanoids. Prostaglandins are rapidly inactivated and in most mammalian 
tissues this rapid metabolism is caused by the enzyme 15- 
hydroxyprostaglandin dehydrogenase. Indomethacin can inhibit 
prostaglandin inactivation, and blocking the activity of the catabolic enzyme 
prolongs the half life of prostaglandins. Prostaglandins are not stored in the 
cell but are continuously released to the cell exterior where they act locally 
in a paracrine manner to increase cAMP.
Prostaglandins are potent stimulators of bone resorption (Klein and Raisz, 
1970). PGEi and PGE2 are the most potent whereas PGAi and PGFia also
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increase bone resorption but higher doses are necessary. The stimulation 
of bone resorption is similar to that observed with parathyroid hormone and 
both these agents stimulate cAMP in bone. However, adrenalin also 
stimulates cAMP but has no effect on resorption, suggesting that 
prostaglandins enhance bone resorption by some other mechanism.
The bone resorbing actions of IL-1, TNF and PTH can be inhibited by 
indomethacin but the level of inhibition varies depending on the model used. 
Gowen et a /(1983) reported no inhibition of IL-1 induced bone resorption by 
indomethacin using neonatal mouse calvariae, whereas Akatsu efa/(1991) 
observed a decrease in the number of osteoclasts and IL-1 induced 
resorption in murine foetal long bones coincubated with indomethacin. An 
explanation for this discrepancy may be that murine foetal long bones are at 
an earlier stage of development than calvariae. Dieudonne et al (1991) 
observed that 17day calvariae contain many multinuclear, TRAP positive 
cells that are seen actively resorbing mineralised matrix. 17day metatarsal 
rudiments were less advanced, osteoclasts were not present and excavation 
of a marrow cavity had not yet started. Prostaglandins may be involved in 
the early stages of osteoclast formation but other factors may affect the 
resorptive function of mature osteoclasts. Collins and Chambers (1991) 
report that prostalandins Ei and E2 increased the number of calcitonin 
receptor positive cells in murine bone marrow cultures and enhanced bone 
resorption by these cells when incubated on dentine slices. Similarly Akatsu 
eta l (1991) report that IL-1 a and IL-1 p stimulated osteoclast-like cell 
formation in murine bone marrow and this could be completely inhibited by 
indomethacin. These authors observed a correlation between the number 
of TRAP positive cells formed and the concentration of PGE2 in the culture 
media. In cultures of foetal mouse long bone, indomethacin only partially 
suppressed IL-1 induced bone resorption.
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Prostaglandins mediate the stimulation of resorption by platelet derived 
growth factor, epidermal growth factor, TNFa and TGF-p. Prostaglandins are 
also reported to strongly inhibit resorption by isolated osteoclasts and PGE2 
decreases the bone resorption stimulated by 1,25D using mouse bone 
marrow cultures (Collins and Chambers, 1991).
Prostaglandins may act by stimulation of the formation of osteoclast-like 
cells which are then induced to resorb by other factors. Failure of 
indomethacin to completely block resorption in organ cultures suggests that 
prostaglandins are only partly responsible for the resorptive response to 
IL-1. Numerous steps in the induction of bone resorption are not 
prostaglandin mediated - osteoid degradation mediated by collagenase, 
recruitment of osteoclasts and activation of newly formed osteoclasts. 
Resorption induced by 1,25D and formation of TRAP positive multinuclear 
cells are not affected by indomethacin. Collagenase production induced by 
IL-1 is also reported to be independent of prostaglandins.
It is possible that osteoclast progenitors at advanced stages can be 
differentiated into osteoclasts by a mechanism independent of prostaglandin 
synthesis, whereas immature osteoclast progenitors need prostaglandin for 
IL-1 mediated osteoclast differentiation.
PGE2 also enhances bone formation by stimulating the replication and 
differentiation of osteoblast progenitors (Raisz, 1988a). Osteoblasts release 
PGE2 in response to interleukin 1 (Tatakis, Schneeberger and Dziak, 1988), 
parathyroid hormone (McDonald et al, 1984) and tumour necrosis factor a 
(Sato e ta l, 1987) but gamma interferon depresses PGE2 production by the 
murine clonal MC3T3-E1 cells (Hoffmann etal, 1987). MacDonald eta l 
(1984) report that 1,25D depresses basal production of PGE2 in human 
osteoblast-like cells, whereas Klein-Nulend, Pilbeam and Raisz (1991) 
report a delayed and small stimulatory effect of 1,25D on PGE2 production in 
mouse parietal bones. This latter effect was blocked by the IL-1 receptor
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antagonist (IL-1 Ra) although IL-1 Ra did not block the resorptive effect of 
1,25D. Possibly 1,25D may increase the IL-1 produced by 
monocyte/macrophages in the bone marrow, which in turn causes an 
increase in the release of PGE2.
PGE2 may be involved in the pathological bone loss associated with 
rheumatoid arthritis as prostaglandins are released at sites of inflammation. 
A physiological role for prostaglandin in the control of bone remodelling is 
difficult to assess. Better identification of early and late ostoclast progenitors 
may assist in defining the role of prostaglandins in enhancing osteoclast 
formation.
A) lDteg.ri.ns
In addition to the numerous soluble factors regulating bone turnover and 
the function of bone cells, it is likely that the bone extracellular matrix itself 
can influence the sequence of events of the remodelling cycle. Certain 
noncollagenous proteins of bone possess the amino acid sequence -RGD- 
which is the recognition site of adhesion molecules for the cell surface 
integrins. Integrins are heterodimeric molecules that function as cell- 
substratum or cell-cell adhesion receptors.
Integrins are composed of two noncovalently associated a and p subunits 
that are integral membrane glycoproteins. Six different p subunits have 
been described and certain a subunits can combine with more than one p 
subunit. The a subunit contains areas thought to bind Ca2+. Most integrins 
bind to more than one ligand. A typical p subunit possesses one membrane- 
spanning domain and a short cytoplasmic domain at the carboxy terminus of 
the molecule. On the cytoplasmic side of the plasma membrane, the 
receptors contain regions capable of binding to cytoskeletal proteins such as 
talin, vinculin and actinin and serve to link the extracellular matrix to the 
cytoskeleton. The structure and function of integrins are reviewed by 
Albelda and Buck (1990).
44
Integrins recognise specific (RGD) amino acid sequences in their ligands 
(Humphries, 1990). Adhesive molecules fibronectin, fibrinogen, 
thrombospondin, vitronectin, laminin and type I collagen all possess the 
RGD sequence. Each receptor displays specificity, for example the 
fibronectin receptor binds fibronectin but not vitronectin. Little is known 
about how such specificity is maintained but the confirmation of the RGD 
tripeptide and its surrounding sequences may determine the recognition of 
specific proteins by receptors.
Integrin-mediated attachment of cells to the extracellular matrix may 
stimulate cell migration or promote differentiation. The matrix may act as a 
competence-inducing factor making cells capable of responding to 
hormones or other soluble factors. In addition, binding of cells to the matrix 
may result in conformational changes that in turn provide inductive signals. 
Interaction of the fibronectin receptor with fibronectin results in the induction 
of metalloproteinase and collagenases are released following the binding of 
the laminin receptor with a synthetic peptide derived from laminin 
(Humphries, 1990). Thus the integrins may also play a role in tissue 
breakdown.
The attachment of rat osteoclasts to a number of adhesion molecules was 
studied by Helfrich eta l (1992). Osteoclasts adhered well to the proteins 
osteopontin, BSP, fibronectin, vitronectin, fibrinogen and von Willebrand 
factor, and adhered to a lesser extent to collagen types I and III. The cells 
failed to adhere to laminin, thrombospondin, elastin, osteonectin and 
osteocalcin. A monoclonal antibody recognising the rat p3 chain inhibited 
attachment to all proteins with the exception of type I collagen. The 
attachment of osteoclasts to osteopontin, von Willebrand factor and 
vitronectin could be inhibited with RGD peptides. These results demonstrate 
that attachment of osteoclasts is mediated in part by the binding of RGD- 
containing proteins to p3. Binding of cells to type I collagen may be
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mediated by other receptors. The failure of osteoclasts to attach to 
thrombospondin, which also contains RGD, may reflect the specificity of 
ligand-integrin interactions.
Osteoblasts, in cryostat sections of human bone, have been shown to 
express the a-j, a3, and fa integrin subunits, while osteoclasts express a2 
and fa units and possess the 0 ^ 3  vitronectin receptor (Clover and Gowen, 
submitted). The adhesion properties of the two cell types would appear to 
be differentially regulated, by binding to different adhesion proteins - a 
property that may reflect the very different functions of the two cell types.
1.7 In vitro models for studying osteoblastic function.
Organ cultures of calvariae and long bones from neonatal or foetal rats 
and mice have been used extensively to study the effects of osteotropic 
hormones and cytokines on bone resorption and formation. Using these 
models, information regarding the overall effects of test agents on bone 
resorption (usually measured by release of 45Ca) and bone formation (as 
assessed by incorporation of 3H-proline into collagen) have been obtained. 
With respect to certain agents (e.g. TGFp, IL-6 , PGE2 , E2, described above) 
conflicting data from different model systems serves to highlight the 
differences of differentiation status of the models used, and the 
heterogeneity of the cell populations involved.
For the study of osteoblast-like cell function, cells prepared from foetal 
bovine, murine and rat calvariae have been described and characterised 
(Globus, Patterson-Buckendahl and Gospodarowicz, 1988; Wong and Cohn, 
1975; Bellows etal, 1986). Sequential collagenase digestion techniques 
yield populations of cells enriched for the osteoblast phenotype (Sodek and 
Heersche, 1981). These cell cultures are heterogeneous and do not permit 
the identification of the cell types responding to specific agents.
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A clonal cell line (MC3T3-E1) expressing alkaline phosphatase activity, 
responsive to 1,25D and able to mineralise in vitro has been obtained from 
neonatal murine calvariae (Sudo etal, 1983). Osteosarcoma cell lines of 
both rodent and human origin have been described (for a review see Rodan 
etal, 1988), which provide large numbers of cells for study and have the 
advantage of being clonal in origin but are transformed, fail to express the 
full osteoblast phenotype (Table 1.1) and are unlikely to represent normal 
function. Very few models are available for the study of adult human bone 
cell function. Cultures of human osteoblast-like cells derived from trabecular 
bone express all the hallmarks of the mature osteoblast phenotype such as 
alkaline phosphatase activity, PTH responsive adenylate cyclase, type I 
collagen production and osteocalcin production in response to 1,25D 
(Beresford, Gallagher and Russell, 1986). Table 1.1 shows a summary of 
certain osteoblast models. The models vary in their expression of 
osteoblastic characteristics (e.g. osteocalcin production) which may indicate 
that they represent different stages of the osteoblast lineage.
Heath and co-workers have produced two new bone cell lines by 
immortalisation of rat calvarial osteoblasts with SV-40 DNA (Heath et al,
1989). RCT-3 cells express alkaline phosphatase enzyme which is 
enhanced by 1,25D, and respond to PTH with the production of cAMP. 
mRNA for osteopontin is present and is enhanced by 1.25D, whereas mRNA 
for type I procollagen is downregulated by 1,25D. RCT-1 cells had 
undetectable ALP activity and failed to respond to PTH. However, treatment 
of RCT-1 cells with retinoic acid induced both of these osteoblastic 
characteristics, suggesting that RCT-1 cells represent an osteoblast 
precursor. Use of such immortalised cell lines may yield interesting 
information concerning the control of differentiation in osteoblastic cells.
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Table 1.1. OSTEOBLAST MODEL SYSTEMS
MURINE 
MC3T3 - E1






and Rodan, 1980) 
RCT -1 and -3 







(Franceschi and Young 
1990, Lajeunesse etal,
1990)
High basal alkaline phosphatase activity 
Functional responses to 1,25D 
No elevation of cAMP in response to PTH.
Numerous clones and subclones:
PTH responsive adenylate cyclase,
Alkaline phosphatase activity 
Receptors for 1,25D
High alkaline phosphatase activity 
PTH responsive, produce osteocalcin
Rat calvarial cell lines produced by 
immortalisation with SV-40 large T antigen. 
Osteoblast characteristics induced by retinoic 
acid: mRNA for osteopontin and type I 
collagen, inducible PTH responsiveness. 
Constitutive osteoblast characteristics: 
Respond to IL -1 by increased prostaglandin 
production.
Do not produce osteocalcin in response to 
1,25D.
Human Osteosarcoma cell line.
High alkaline phosphatase 
PTH responsive adenylate cyclase 
Receptors for 1,25D
Produce osteonectin but do not produce 
osteocalcin in response to 1,25D.
Low constitutive ALP enhanced by 1,25D. 
Produce osteocalcin in response to 1,25D.
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1.8 Objectives of study
The study of osteoblast function in vitro relies heavily on the availability of 
model systems representing the normal osteoblast phenotype. Murine cells 
have the capacity to form continuously growing cultures spontaneously 
permitting the isolation of clonal osteoblast -like cells from neonatal mouse 
calvariae. Human cells fail to form spontaneously growing cell lines, thereby 
limiting the number of model systems available for the study of adult human 
bone cell function.
Human osteoblast-like cells obtained as outgrowths from trabecular bone 
express many of the classical characteristics of osteoblasts. These cells 
produce type I collagen, express alkaline phosphatase (ALP) activity and 
display PTH-responsive adenylate cyclase. In addition, the cells produce 
osteocalcin in response to 1,25-di hydroxy vitamin D3 . However, these 
cultures are heterogeneous and may include not only osteoblastic cells at 
various stages of differentiation but also other cell types such as fibroblasts 
and marrow stromal cells. Such heterogeneity limits the identification of 
specific cells responsive to osteotropic hormones and cytokines.
Osteosarcoma cell lines express many of the characteristics of osteoblasts 
but these cells are transformed and may not represent normal function.
The objectives of this study were to attempt to immortalise human osteoblast­
like cells in order to obtain discrete cell lines expressing the osteoblast 






Minimum essential medium (MEM), Roswell Park Memorial Institute 
Medium (RPMI), Dulbecco's modification of Eagle's medium (DMEM), L- 
glutamine, penicillin and streptomycin were obtained from GIBCO BRL 
(Paisley, UK). Foetal calf serum (FCS) was obtained from Imperial 
Laboratories (Andover, UK). 1,25-dihydroxyvitamin D3 (1,25D) was a kind 
gift from Dr. M. R. Uskokovic, Hoffmann La Roche (Nutley, NJ). Simian Virus 
40 (SV40) DNA was a gift from Dr. Vittoria Marini, University College and 
Middlesex School of Medicine (London, UK). A calcium phosphate 
transfection kit was purchased from 5 prime, 3 prime Inc. (West Chester, PA).
Recombinant human interleukin 1a (rhlL-1a) was a gift from Glaxo Group 
Research (Middlesex, UK). Recombinant human tumour necrosis factor a 
(rhTNFa) was purchased from Genzyme Corporation (Boston, MA). rhlL-6  
was a gift from Dr. L.A. Aarden and had a specific activity of 109U/mg. A 
cDNA probe for type I collagen was a gift from Dr. R. Poulsom, ICRF (London, 
UK). cDNA probes for IL-1 p, TGFp and p actin were a gift from Glaxo Group 
Research. Immunoradiometric assay kits for the detection of TNFa were 
supplied by Medgenix diagnostics (Brussels, Belgium).
A monoclonal antibody directed against the common epitope of SV40 
large T and small t antigens was obtained from Oncogene Science Inc. 
(Manhasset, NY). Radioisotopes and multiprime DNA labelling system kits 
were supplied by Amersham International (Amersham, UK). Other 
chemicals were supplied by Sigma Chemical Company (Dorset, UK). 
Multiwell plates and tissue culture dishes were obtained from Costar 
(Cambridge, MA).
22  Patient details
Trabecular bone-derived cells were prepared from fragments of bone 
obtained from a 17 year old male. The patient had undergone a 
supercondylar osteotomy of the left femur for genus varum recurvatum. This
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was necessary due to stapling of the medial aspects of the knees four years 
previously which had overcorrected growth on the left side. The patient had 
received no drugs and had no known underlying bone disorder.
2.3 Human bone cell culture.
Human osteoblast-like cells were isolated by maintaining explants of 
trabecular bone in culture. Cells isolated by this method have been well 
characterised and express markers of the osteoblast phenotype. The cells 
express alkaline phosphatase enzyme, produce osteocalcin in response to 
1,25D, produce type I collagen and display a PTH-responsive adenylate 
cyclase (Beresford etal, 1984, MacDonald, Gallagher and Russell, 1986).
Trabecular bone was obtained from a 17 year old male (femoral osteotomy) 
and excised into 3-5mm pieces. Bone chips were washed several times in 
phosphate buffered saline (PBS) to remove any blood and loosely adherent 
marrow cells, and incubated overnight at 37°C in universal containers filled 
with complete MEM. The purpose of this overnight incubation is to allow fat 
globules from the bone to rise to the surface of the medium. Removal of fat in 
this way improves the yield of cells obtained from the chips as fat deposited 
on the tissue culture plastic decreases the area available for osteoblasts to 
settle.
Following this incubation, the medium was decanted and the bone explants 
washed again in PBS. Bone chips were then incubated in 1 0 0 mm tissue 
culture dishes in 10ml per dish of complete MEM. The medium was changed 
every week until confluent monolayers of cells were obtained.
2.4 Maintenance of cell lines
Immortalised osteoblast-like cell lines (Bath Osteoblast Prototype (BOP)), 
and human osteosarcoma cells (MG-63) were maintained in Minimum 
Essential Medium supplemented with 10% foetal calf serum +2mM L- 
glutamine, 100IU/ml penicillin and 100jig/ml streptomycin (complete MEM). 
COS cells were maintained in DMEM with the same additions. The cells
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were cultured in 1 0 0 mm tissue culture dishes with 1 0 ml of complete 
medium, which was replaced every 3-4 days. Primary cultures of 
osteoblasts and all cell lines were passaged using the following procedure: 
Culture medium was aspirated and the cell layer washed once with 1 0 ml 
PBS, cell layers were incubated with 2.5ml per culture dish of trypsin 
(0.25%) + EDTA (0.2%) for 5-10 minutes at 37°C, the reaction was stopped 
by addition of complete medium and the cell suspension centrifuged for 
5min at 230g. Cells were resuspended and counted using a 
haemocytometer.
2.5 Alkaline phosphatase and bone matrix proteins 
BOP cells were passaged and seeded into 6  well plates at 4 X 104 per 
30mm well and allowed to settle for 24h in complete medium. The medium 
was then changed to defined medium (MEM + 0.1% bovine serum albumin, 
1ng/ml insulin, 10|ig/ml transferrin and 3 X 10_8M NaSe0 2 ) supplemented 
with 50^g/ml L-ascorbate and 10’8M vitamin Ki. After 24h the medium was 
changed again to defined medium + L-ascorbate and vitamin Ki with either 
ethanol vehicle or 1 0_8M 1,25D. Cultures were incubated for a further 48h 
and the conditioned media obtained stored at -20°C for the determination of 
bone matrix proteins. Cell layers were freed by addition of 500^1 per well of 
0.1% tween followed by scraping with a rubber policeman. Cell layers were 
sonicated for 5s (amplitude 15 microns). Alkaline phosphatase (ALP) activity 
and total protein content were determined on aliquots of sonicated cell 
samples.
a). Alkaline phosphatase assay 
ALP activity in cell sonicates was measured by monitoring the release of 
para-nitrophenol from disodium p-nitrophenyl phosphate at 37°C and pH 
10.5. The reaction produces a coloured product and can be monitored 
spectrophotometrically at 410nm.
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A standard curve was obtained by preparing serial dilutions of a 10jj.mol/ml 
stock of p-nitrophenol. The stock solution was diluted in 0.1% tween to obtain 
standards of 2, 1.8, 1.6, 1.4,1.2,1.0, 0.8, 0.6, 0.4, 0.2, 0.1, and 0.05nmol/ml. 
Assay buffer was prepared as follows: 10.52g diethanolamine and 400mg 
magnesium chloride were dissolved in distilled water and the pH adjusted to 
10.5 with 0.1 M HCI. Immediately prior to the assay, 46.4mg of disodium p- 
nitrophenyl phosphate were added to 1 0 0 ml of buffer.
50iil of each sample or standard were pipetted into a LP3 tube and the 
reaction started with 500|xl of assay buffer. The tubes were incubated at 
37°C for 30-60min until a yellow colour developed. The reaction was 
stopped with 1 ml 0.2M NaOH when the colour of the samples matched that of 
the lower standards. The reaction time was noted and 200^1 of each sample 
and standard were transferred to wells of a 96 well plate. Absorbance at 
410nm was measured using a Dynatech micro-ELISA reader. A standard 
curve of p-nitrophenol concentration (abscissa) vs absorbance (ordinate) was 
plotted and sample results extrapolated. Results are expressed as ^moles 
per min per mg total protein.
SL Total protein assay
The protein content of the cell sonicates was measured by the method of 
Lowry (Lowry eta l 1951). This method is based on the reduction of 
phosphomolybdic-tungstic acid present in Folin and Ciocalteu reagent. 
Proteins effect a reduction by the loss of oxygen atoms from the mixed acid 
thereby producing a blue colour with maximum absorbance at 745-750nm. 
Copper is though to facilitate electron transfer to the mixed acid and so 
serves to increase the sensitivity to protein.
Bovine serum albumin (BSA) was used as standard. Serial dilutions of 
BSA in 0.1% tween were prepared to give standards of 100, 87.5, 75, 62.5,
50, 37.5, 25, 12.5, 7.5, and 5ng protein in 100^ 1.
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The following reagents were prepared:
Copper stock solution:
1% (w/v) tri-sodium citrate dihydrate in 0.5% (w/v) cupric sulphate 
(CuS04 .5H20).
Alkaline stock solution:
10% (w/v) anhydrous Na2CC>3 in 2 % (w/v) NaOH.
Folin's reagent:
Stock diluted 1:2 parts with dH20, immediately prior to use.
Alkaline copper reagent was freshly prepared immediately prior to the 
assay by mixing 1 ml copper stock solution, 2 0 ml alkaline stock solution and 
79ml dH20. 100^1 of standard and sample were pipetted into LP3 tubes and 
500|xl of alkaline copper reagent added. Tubes were vortexed and left to 
stand for 10min at room temperature. 50^ 1 of Folin’s reagent were added, the 
tubes vortexed again and incubated at room temperature for 30min. 200^1 of 
each standard and sample were transferred to wells of a 96-well plate and 
the absorbance at 750nm measured using a plate reader. A standard curve 
of protein concentration (abscissa) vs absorbance (ordinate) was plotted and 
sample results extrapolated. 
cV Osteocalcin assay 
Osteocalcin, released into the experimental culture medium, was measured 
using a specific radioimmunoassay. Radiolabelled osteocalcin (125 l- 
osteocalcin) and cold osteocalcin, in standards or samples, compete for 
binding sites on the primary antibody (rabbit anti-bovine osteocalcin). A 
second antibody (goat anti-rabbit gammaglobulin) is used to precipitate the 
osteocalcin-primary antibody complex. Normal rabbit serum (2% v/v) was 
added to the tubes to produce a larger, more visible pellet. The amount of 
incorporated radioactivity in the precipitated pellet was monitored with a 
gamma counter.
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The assay buffer used was Bent T (0.01 M Tris pH 7.4, 0.14M NaCI, 0.025M 
EDTA, 0.1% tween, 0.25% BSA). A standard curve of purified bovine 
osteocalcin was prepared by serial dilution to give standards of 100, 50, 33, 
20, 10, 5, 3.3, 2, and 1ng/ml.
50|xt of standard and sample were transferred to LP4 tubes, 50^ 1 of 2% 
normal rabbit serum (NRS), 50^ 1 of primary antibody and 100jil of Bent T 
were added and the tubes vortexed. Finally, 50jil of i 25 l-osteocalcin were 
added. The tubes were vortexed again, covered, and incubated at 4°C 
overnight. In addition, the following control tubes were included: Non specific 
binding (NSB), included as a quality control to account for non specific 
binding of the radiolabel. NSB tubes contained 100^ 1 of NRS, 150|xl Bent T 
and 50|xl of 125l-osteocalcin. Maximum binding (MAX) was included to 
account for the binding of 125l-osteocalcin to primary antibody in the absence 
of cold, competing osteocalcin. MAX tubes contained 50^ 1 of primary 
antibody, 150^ 1 Bent T and 50^1125l-osteocalcin. Total counts (TC) (125l- 
osteocalcin alone) was included as an interassay quality control.
Following the first overnight incubation, 50|il of second antibody and 500^1
of buffer were added to all tubes except TC. Tubes were vortexed and
incubated again at 4°C overnight. Tubes were then centrifuged for 25min. at
2,000g and 1 0°C. Supernatant was aspirated and the amount of radioactivity
in the tubes monitored. A graph of logio concentration (abscissa) vs B/Bo
(ordinate) was plotted where B/Bo is calculated from the following equation:
B/Bo = Counts per min. (standard/samplel-NSB
MAX-NSB
A typical standard curve is shown in figure 2.1. Results were extrapolated 
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Fig. 2.1 A typical standard curve for the osteocalcin assay
57
2 .6  Immunofluorescence 
In order to assess the ability of transfected cell lines to express SV40 early 
gene products, indirect immunofluorescence was carried out using a 
monoclonal antibody directed against the common epitope of SV40 large T 
and small t antigens. Cells (at 103 per spot) were allowed to settle 
overnight onto poly-L-lysine coated multispot slides then slides were 
washed in PBS and fixed in acetone for 1 0 min at room temperature. Slides 
were incubated for 30min in a humidified chamber at room temperature with 
optimally diluted primary antibody. Negative control spots incubated with 
mouse serum were included. Slides were washed in PBS+2% FCS over 
30min and incubated with fluorescein isothiocyanate (FITC)-conjugated goat 
anti-mouse (polyvalent IgG) optimally diluted in PBS+2% FCS+2% human 
AB serum. The AB serum is included to block non-specific binding of the 
FITC conjugate to human antigens on the cell surface. After 30min at room 
temperature slides were washed again and mounted in 90% (v/v) glycerol in 
PBS+2.5% (w/v) diazo-bicyclo-octane (DABCO). The DABCO prevents 
quenching of the fluorescence.
22  Molecular Biology Reagents
1 0X MOPS -  2 0 0 mM 3-(N-morpholino) propanesulphonic acid,
50X Denhardt's --
2 0 X SSPE -
20XSSC -
10X Tris EDTA -
1 0X Tris acetate --
50mM sodium acetate, 10mM ethylenediamine 
tetraacetic acid (EDTA)
175.3g/l NaCI, 8 8 .2 g/l sodium citrate pH 7 
175.3g/l NaCI, 27.6g/l NaH2P04, 7.4g/l EDTA 
5g Ficoll, 5g polyninylpyrrolidone (PVP), 5g 
BSA in 500ml of deionised water.
0.4M Tris, 0.05M sodium acetate, 0.01 M EDTA 
pH 8.1.
1 0 0 mM Tris, pH 7.4, 10mM EDTA pH 8 .
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RNA loading dye -  20% (w/v) Ficoll, 0.2% (w/v) bromophenol blue.
DNA loading dye -  25% Ficoll, 0.25% bromophenol blue, 0.25%
xylene cyanol.
2 3  RNA isolation
RNA was isolated from ceils maintained in 100mm culture dishes. Medium 
was aspirated and 0.5ml guanidium thiocyanate + 0.1 M 2-mercaptoethanol 
(solution D) added to each petri dish. Cell layers were removed using a 
sterile cell scraper and transferred to microfuge tubes. RNA was extracted 
from the cell layers using the method of Chomczynski and Sacchi (1987).
To 0.5ml of cell lysate, 5 0 jllI of 2M sodium acetate (pH 4), 500^1 phenol 
(water saturated) and 100^ 1 chloroform-isoamyl alcohol (49:1) were added 
sequentially and tubes were mixed by inversion between each addition. 
Tubes were shaken vigorously and allowed to cool on ice for 15min. Tubes 
were microfuged at 11,600g for 5min and the aqueous layer decanted into a 
fresh tube. An equal volume of chloroform-isoamyl alcohol was added, 
tubes were centrifuged again and the aqueous layer decanted. An equal 
volume of isopropanol was added to the final aqueous layer and the 
microfuge tubes stored at -20°C overnight to precipitate the RNA.
Following the overnight step, RNA was microfuged at 11,600g for 10min. 
The supernatant was discarded and the pellet redissolved in 150^ 1 of 
solution D. 150pJ of isopropanol were added and the RNA precipitated 
again at -20°C overnight. The RNA was then microfuged again for 10min 
and the pellet washed twice in 70% ethanol and once in absolute ethanol. 
The pellet was dried in a vacuum chamber and then redissolved in 50|xl of 
diethyl-pyrocarbonate (DEPC) treated water.
RNA was quantified by measuring the absorbance at 260nm and 280nm. 
The ratio A260/A280 should be 2.0 for RNA, a lower ratio indicates the
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presence of contaminating phenol or protein. The concentration of RNA is 
calculated from the following equation: A260 X 40 X dilution = ng/ml RNA 
2£ Hybridisation of filters
Filters of RNA obtained by Slot and Northern blotting were prehybridised 
for 4h at 50°C in a pretreatment solution of 2X SSC, 10X Denhardt's, 33% 
(v/v) formamide, 10% (w/v) dextran sulphate, 0.5% (w/v) sodium dodecyl 
sulphate (SDS), 2mM EDTA and 10mg/ml denatured salmon sperm DNA 
(ssDNA). The ssDNA is included to prevent non-specific binding of the 
probe to the filter.
cDNA probes were labelled by the random hexanucleotide method using a 
Multiprime DNA labelling system (Amersham International U.K.). Linear 
double stranded DNA is denatured and added to Multiprime DNA labeling 
buffer which contains deoxy-adenine triphosphate (dATP), deoxy-guanine 
triphosphate (dGTP) and deoxy-thymidine triphosphate (dTTP) in Tris-HCI, 
pH7.8, magnesium chloride and 2-mercaptoethanol. Random sequence 
hexamers (primer solution) are added which recognise complementary 
sequences on the probe DNA strand and bind. The 'Klenow' fragment of 
DNA polymerase I initiates synthesis of DNA strands which are 
complementary to the probe and are radiolabelled by addition of 32P deoxy- 
cytosine triphosphate (32PdCTP).
The labelling procedure is as follows:
10-20ng of probe DNA (1 -1 0m.I) are added to sufficient deionised water to 
make a final volume of 25jJ in a small eppendorf tube. The probe is heated 
in a boiling water bath for 5min to denature the DNA and the tube quenched 
on ice. 5^ 1 of buffer, 2.5^1 of primer, 2.5^1 of 32PdCTP and V I of enzyme 
(Klenow) are added and the reaction allowed to proceed for 3-5h at room 
temperature. At the end of the incubation 75jxl of water are added and the 
reaction stopped with V I of 500mM EDTA (final concentration 20mM EDTA). 
The enzyme requires Ca2+ and Mg2+ ions for the reaction to proceed, EDTA
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binds these ions and thus stops the reaction. The probe is boiled again to 
release single stranded labelled DNA fragments and added to the 
hybridisation mixture.
Filters were hybridised at 50°C overnight and then subjected to high 
stringency washing. Filters were washed for 2 h at 65°C in prewarmed buffer 
(2 X SSC, 0.5% SDS), for 15min in 0.1 X SSC and rinsed finally in 2 X SSC. 
The filters were wrapped in cling film and exposed to X ray film in cassettes 
with intensifying screens. Films were developed after 24-72h.
To normalise the signal for equal loading of the RNA, filters were stripped 
by soaking in a boiling solution of 0.5% SDS which was allowed to cool to 










With a view to obtaining a self-renewing population of cells expressing the 
osteoblast phenotype, primary cultures of trabecular bone-derived cells 
were transfected with SV40 DNA using the calcium phosphate/DNA co­
precipitation technique. 1-2  weeks post-transfection numerous foci of mitotic 
cells appeared in the transfected population. The colonies were plucked 
and rapidly expanded to provide large numbers of cells. The cell lines 
expressed the enzyme alkaline phosphatase and certain cell lines 
responded to 1,25D by increased enzyme activity. In order to obtain clonal 
osteoblast-like cell lines, two lines were cloned by limiting dilution. Many of 
the clones entered crisis and senesced but two clonal cell lines survived and 
expressed very high levels of alkaline phospatase. Immortalisation of 
primary cells is a useful technique for obtaining large numbers of cells 
expressing the parent phenotype. The cell lines have been given the name 
BOP for Bath Osteoblast Prototype.
3.1 INTRODUCTION
Primary cultures of cells, obtained as outgrowths from tissues and organs, 
provide useful models for in vitro studies of cell function. Rodent cells form 
continuous cell lines in culture spontaneously whereas human cells survive 
only a limited number of generations in vitro. Clonal cell lines expressing 
the full phenotype of the mature osteoblast have been obtained by digestion 
of murine calvariae (Sudo et al, 1983). Clonal cells of human origin are 
more difficult to obtain, but are desirable as species differences occur with 
respect to the effects of hormones and cytokines on cells. Furthermore, 
studies on animal cells may not be directly relevant to the understanding of 
disorders of bone metabolism in humans.
Human osteoblast-like cells, derived from explants of trabecular bone 
obtained at surgery, have been well characterised and express all the
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hallmarks of the mature osteoblast. The responses of these cells to 
calciotropic hormones, growth factors and immune-cell derived cytokines 
have been explored extensively and are more fully described in chapters 4 
and 5. The disadvantages of these primary cultures are their limited 
capacity for growth in vitro, making them difficult to obtain in large numbers, 
and the heterogeneity of the trabecular bone cell population. Cells of 
different stages of the osteoblast differentiation pathway are likely to be 
present and contamination by other cell types, such as fibroblasts and 
marrow stromal cells, may also occur.
To overcome these problems osteosarcoma cell lines of human origin 
have been described and used for a variety of biochemical studies, large 
numbers of clonal cells are readily obtained and are convenient for in vitro 
use. The cells express some of the characteristics of mature osteoblasts but 
not all the phenotypic markers are present in a particular cell line. The 
transformed nature of the osteosarcoma cell lines may account for 
alterations in responsiveness to various hormones, and the loss of certain 
osteoblastic characteristics.
The technique of immortalising cells by transfection with oncogenic viruses 
and exogenous DNA has been widely used both to study the molecular and 
genetic events leading to transformation of cells, and to provide rapidly 
growing populations of cells derived from primary cultures. Rodent cells are 
more readily transformed by cellular oncogenes than are human cells, 
transfection with an oncogenic virus such as simian virus 40 (SV40) has 
proved more successful as an inducer of anchorage independent growth 
and loss of contact inhibition in human cells (Mayne etai, 1986, Oshima et 
ai, 1977, Huschtscha and Holliday, 1983).
Land, Parada and Weinberg (1983) describe the transformation of rat 
embryo fibroblasts (REF) using the ras and myc oncogenes. When REF 
cells were transfected with either cloned ras or myc oncogenes the cells
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failed to transform as assessed by their inability to form colonies in soft agar. 
When cells were cotransfected with both ras and myc oncogenes, 
anchorage independent growth was induced and the cells produced rapidly 
growing fibrosarcomas in nude mice. Thus for the tumorigenic conversion of 
primary fibroblasts, expression of a single oncogene was insufficient.
Simian virus 40 (SV40) is a member of the papova group of small, 
nonenveloped DNA viruses and causes lytic infection of permissive monkey 
cells. The genome of SV40 contains an early region encoding the large T 
and small t tumour antigens, the late region encodes the viral coat proteins. 
The origin of replication (ori) is found between the early and late regions.
The SV40 T antigen is a large multifunctional protein of 90,000 daltons that 
binds specifically to the SV40 origin of replication and acts as an initiator of 
DNA replication (Myers etal, 1981).
SV40 has been used to transform a wide range of cell types such as 
human fibroblasts (Huschtscha and Holliday, 1983; Oshima etal, 1977), 
human juxtaglomerular cells (Pinet etal, 1985) bone marrow cultures 
(Singer etal, 1987) and rat calvarial osteoblasts (Heath etal, 1989). Table
3.1 shows a variety of vectors that were used in an attempt to transform 
pancreatic (3 islet cells and thyroid epithelial cells (Marini, personal 
communication). SV40 was the only vector capable of establishing a cell 
line from these primary cultures. SV40 would seem to be far more potent at 
inducing rapid cell growth and loss of contact inhibition in cells than cellular 
oncogenes.
Small, Gluzman and Ozer (1982) describe the transformation of human 
fibroblasts with both wild-type SV40 and an SV40 construct that lacked the 
origin of DNA replication (ori-). The vector SV40 pSV ori- was demonstrably 
more efficient at inducing a loss of contact inhibition and inducing 
anchorage independent growth of transfected cells. When transfected cells 
were grown in soft agar, a greater number of larger colonies were obtained
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VECTORS Line established from: Reference Times tried and No. of lines established:
Pancreas Thyroid
SV40(pX-8) RatF-11 Fromm and Berg, 1982 12 2 33 1
__________________ Human fibroblasts Mayne et al, 1986_________________________________________
SV40 (PAS) Human juxtaglomerular 
cell tumour
Pi net etal, 1985 10 1 21 1
pSV Neo Human thyrocytes Whitley et al, 1987 8 13 •
Adenovirus Ad 12S/13S Baby rat kidney cells Haley et al, 1984 7 _ 11 _
c-myc (SV40 promoter) Rat embryo fibroblasts Land, Parada and 5 - 4 -
and v-myc Weinberg, 1983 5 - 4 -
Table 3.1 Vectors used to immortalise pancreatic p islet cells and thyroid epithelial cells. Cell lines were successfully 
established by transfection with SV40 DNA.
from cells transfected with ori- than with wild type SV40. These authors 
suggest that the enhanced transformation efficiency of the origin defective 
vector was due to its inability to replicate in semipermissive cells.
Expression of the SV40 large T antigen is thought to be essential for 
inducing focus formation by transfected cells. Human fibroblasts transfected 
with an SV40 construct lacking the T antigen sequences displayed contact - 
inhibited growth and no morphological transformation occurred (Mayne etal, 
1986). Further evidence of a role for T antigen in the initiation and 
maintenance of immortalisation was provided by Radna et al (1989). These 
workers isolated transformants after introduction of an origin-defective SV40 
genome encoding a heat-labile large T antigen. The transformed human 
fibroblasts grew rapidly at 35°C but failed to form colonies at 39°C, whereas 
cells transfected with wild-type T antigen were able to grow rapidly at the 
higher temperature.
A characteristic of SV40 transformed cells is an initial limited growth 
potential. After a number of generations the cells enter a non-proliferating 
degenerative stage termed "crisis" and many cells senesce. A few cells are 
capable of rejuvenating from crisis and continue growing to form stable, 
post-crisis lines that can proliferate indefinitely. The frequency of such 
stable cell lines occurring is very low (Huschtscha and Holliday, 1982).
A number of techniques have been employed to facilitate the entry of 
exogenous DNA into cells in order to transform them. The efficiency of 
stable transfection varies widely depending on the cell type under study as 
different cells vary in their ability to take up and express exogenously added 
DNA. The most widely used method is transfection mediated by either 
calcium phosphate or DEAE-dextran. The mechanism of action of DEAE- 
dextran is not known but it is thought that binding of the polymer to DNA may 
promote endocytosis of the DNA. Transfection by DEAE- dextran is 
generally used only for transient expression of cloned genes rather than for
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stable transfection. The technique is unsatisfactory for many cell types 
which may be due to the polymer's toxicity (Sambrook, Fritsch and Maniatis, 
1989).
Uptake of DNA into cells may be markedly enhanced if calcium chloride is 
added to the DNA prior to addition to the cell monolayers (Graham and van 
der Eb, 1973). Formation of a calcium phosphate/DNA coprecipitate by 
mixing calcium chloride with sodium hydrogen phosphate is now a well- 
established method for transfecting cells. The precipitate is adsorbed onto 
the surface of the infected cells and may facilitate the entry of DNA into the 
cell by endocytosis, although the precise mechanism is unknown.
For cells resistant to transfection by the calcium phosphate technique, the 
use of pulsed electric fields (electroporation) to introduce DNA into cells has 
a high degree of efficiency of transformation. Brief, high voltage electric 
fields are passed through the cells to induce the uptake of DNA presumably 
through transient micropores in the cell membrane (Andreason and Evans,
1989). Disadvantages of this technique are that optimal conditions of field 
strength, length of pulse and temperature must be determined for every cell 
type studied and the cell viability of electroporated cells is very low (20-50% 
of cells survive) (Sambrook, Fritsch and Maniatis, 1989; Aizawa etal, 1990).
For the immortalisation of human trabecular bone-derived cells, the 
calcium phosphate/DNA coprecipitation technique was employed using a 
SV40 origin defective construct (called px-8 ). Following incubation of the 
cell monolayers with the precipitate, cells were subjected to a glycerol 
shock. This modification may further facilitate the uptake of DNA by the cells 




Definition of the SV40 vector 
Human osteoblast-like cells were transfected with a recombinant vector 
consisting of a 2.3 Kb portion of the plasmid pBR322, SV40 late region, and
SV40 early region DNA which encodes large T and small t antigens. Ori, the
v
sequence needed for initiation of SV40 DNA, was deleted by clea/age of the 
Bgl I site followed by Bal 31 exonuclease digest of each end with insertion of 
the 8 bp Xhol linker. The resultant pX-8  vector was shown to have a 
transforming efficiency of 100% of wild-type SV40 DNA. However, pX-8  fails 
to grow and replicate its DNA when transfected into COS cells (Fromm and 
Berg 1982).
Definition of the pX-8  vector was carried out by restriction endonuclease 
digests of vector DNA. The following restriction enzymes were used:-
1.Xhol single digest
2. Eco Rl single digest
3. Bam HI and Xho I double digest
4. Bam HI and Hpa II double digest
5. Pst I single digest
2 ng of plasmid DNA, in each of 5 microfuge tubes, were dissolved in water 
to make a final volume of 2 0 jxl. 2 |il of the appropriate buffer for the enzyme 
used was added to each tube with 1^ 1 of enzyme. All tubes were incubated 
in a 37°C water bath for 1 h. 2^ 1 of DNA loading buffer were then added to 
the tubes. DNA digests were electrophoresed on a 0.8% agarose gel with 
0.01% ethidium bromide for 1h with a 50mV charge. Commercially obtained 
molecular size markers were included on the gel. These were EcoR I and 
Hind III digests of aDNA, and a Hind III digest of \  DNA.
69
Following electrophoresis the gel was photographed on a UV light 
transilluminator, with a ruler placed next to the gel to allow measurement of 
the distance travelled by the DNA fragments. A graph of logto base pairs 
(ordinate) versus distance moved in mm (abscissa) was plotted for the 
molecular markers. The size of DNA fragments obtained by restriction 
endonuclease digests of pX-8  could then be calculated by extrapolation 
from the curve.
Transfection of osteoblast-like cells
Primary cultures of osteoblasts were seeded at 5 X 105 cells per 100mm 
tissue culture dish and maintained in the presence of bone explants in 
complete MEM for 18h prior to transfection. After 14h explants were removed 
and the medium replaced with fresh complete tissue culture medium.
Plasmid DNA, sterilised in absolute ethanol, was dissolved in 10mM Tris 
pH 8 , 1 mM EDTA. A Ca3 (P O ^ / DNA co-precipitate was prepared by 
adding 500*il of 2X DNA precipitation buffer (50mM Hepes, pH 7.05, 1.5mM 
Na2HP0 4 , 1 0 mM KCI, 280mM NaCI, 1 2 mM glucose) to 62^ 1 of 2 M CaCl2 
with 20^g plasmid DNA and sterile dH2 0  to a final volume of 1 ml. The 
solutions were mixed in a microfuge tube in the presence of bubbling air and 
the precipitate allowed to form for 2 0 min at room temperature. 1 ml of 
precipitate was added to the 1 0 ml of complete medium in each 1 0 0 mm 
tissue culture dish. Cells were incubated at 37°C for 4h. Cell layers were 
then washed with serum free medium and subjected to a glycerol shock.
1 ml of glycerol shocking buffer (3 parts glycerol, 7 parts dH2 0 , 10 parts 
2XDNA precipitation buffer) was added to each cell layer in the absence of 
medium and the cells were incubated for 2 min at room temperature. The 
glycerol was then aspirated and the cell layers were washed again in serum 
free MEM and maintained in complete medium. The culture medium was 
changed every 3-4 days until colonies of mitotic cells appeared 1-2 weeks 
post transfection. A total of 19 100mm dishes were treated in this way.
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Culture dishes were placed under an inverted microscope stationed inside 
a laminar flow cabinet. Individual colonies were plucked using finely drawn- 
out Pasteur pipettes. Colonies were transferred into microfuge tubes, 
centrifuged for 5min. at low speed, washed once in PBS and dispersed with 
trypsin/EDTA. The reaction was stopped with 1ml complete medium, the 
tubes were centrifuged again and the colonies resuspended in 500nl 
complete medium. Individual colonies were seeded into separate 16mm 
wells of 48 well plates and colonies were numbered.
At confluence, cell lines were passaged as described in Chapter 2 and 
expanded into 24-well plates. Cell lines were then passaged again, 
counted, and seeded into 30mm wells with approximately 104 cells of each 
line seeded into microtitre wells. Cells in microtitre wells were allowed to 
settle for 24h then incubated for 72 or 96h with or without 10‘8M 1,25D in 
MEM+ 5% charcoal stripped FCS (CSFCS) supplemented with vitamin Ki, 
and ascorbate. Medium from the wells was discarded, cell layers washed 
with PBS, and ALP assays performed by addition of assay buffer directly to 
the cell layers. Cells in 6 well plates were expanded to 60mm tissue culture 
dishes and then to 1 0 0 mm culture dishes. Cells were continuously 
maintained in 1 0 0 mm culture dishes and cryopreserved.
Cloning bv Limiting Dilution 
Two cell lines, BOP 26 and 37 were cloned by limiting dilution. Cells were 
passaged as described in Chapter 2 , counted, and resuspended to a cell 
density of 5 cells/ml in complete culture medium. 200^1 of cell suspension 
were added to each well of 5 96-well microtitre plates, to give a cell density 
of one cell per well. Cell suspensions of 5 cells/2 ml and 25 cells/ml were 
also prepared and used to seed 5 microtitre plates each, at 1 cell per two 
wells and 5 cells per well respectively.
Every 3-4 days the medium in the wells was replaced with fresh culture 
medium supplemented with medium conditioned by the parent cell line.
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Growth of the cells was monitored daily by viewing plates under an inverted 
microscope. Confluent wells were identified and individual clones 
harvested as follows: medium was aspirated and the cell layers washed 
with 200^1 of PBS. Wells were incubated for 5min at 37°C with 50^ 1 of 
trypsin/EDTA per well. 200jj.I of complete medium were then added to each 
cell suspension. Individual clones were labelled alphabetically (e.g. 37A-Z, 
37AA-WW) and expanded. Two reclones of each cell line (37WW, 26A) 
were subjected to a further round of limiting dilution cloning, in the manner 
described above. Clones of 37WW and 26A (labelled in numerical order) 
were expanded and cryopreserved.
Characterisation of reclones
Clones 26A4, 26A5, 26A12, 37WW3, 37WW5 and 37WW8 were revived 
and maintained in complete culture medium. Cells of two clones, 37WW3 
and 37WW8, were seeded at 4X104/ml in 24-well dishes and allowed to 
settle for 24h. Cells were treated with 10_8M 1,25D in fresh defined medium 
for 48h and cell layers were harvested for ALP assay and total protein as 
detailed in Chapter 2 .
Cell division time
Cells of line BOP 26 were seeded at 4 X104/ml in 24-well culture dishes 
and allowed to settle for 6 h. Cells from 4 wells were harvested with 
trypsin/EDTA, resuspended in complete medium and counted with a 
Nebauer haemocytometer. 4 wells were counted every 24h and in all other 
wells half the medium was replaced daily. To provide a comparison a 
similar growth curve was obtained with cells of the human osteosarcoma 
line MG-63. Primary cultures of human osteoblast-like cells were seeded at 
2X104/ml and counted daily (growth curve provided by J. Clover).
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3.3 RESULTS
Definition of the SV40 vector 
The linearised pX-8  vector was approximately 7.6 Kb in size. The 
fragments obtained by restriction endonuclease digest are shown in table
3.2, following extrapolation of distance moved through the gel from the 
graph (Figure 3.1). The SV40 early region was found to be 3Kb in size, 
1.5Kb smaller than was reported by Fromm and Berg (1982). The 3Kb 
fragment containing early region genes was subsequently used for 
hybridisation of southern blots (see chapter 4). The SV40 late region was 
1.44Kb in size.
Focus formation bv transfected cells 
1 -2  weeks post-transfection, numerous foci of rounded, mitotic cells were 
observed in every plate of transfected cultures. Such colonies do not 
appear in primary cultures of normal trabecular bone cells. Initially, a total of 
82 foci were plucked and dispersed as described in the methods sections of 
this chapter. Certain colonies were lost in the dispersion procedure, some 
colonies failed to grow and one was lost through bacterial contamination. Of 
24 colonies that survived further expansion, 12 were able to support 
continuous, rapid growth in vitro and could be maintained for several 
passages. These cell lines were cryopreserved and quickly and readily 
revived after thawing.
The original parent cultures of transfected cells were returned to the 
incubator and 3 weeks later many more colonies were plucked. These were 
expanded and provided a further 62 cell lines all of which were 
cryospreserved after 4-5 passages.
The appearance of the colonies of mitotic cells, observed under phase 
contrast microscopy, is shown in figure 3.3(a). The phenotypic alteration of 
the cells, indicative of a loss of contact inhibition of growth, was also 
observed in post confluent cultures after a number of passages. Fig. 3.3b
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shows a typical focus of mitotic cells observed in cell line number 4 at 
passage 4. After the first 12 cell lines had been maintained in culture for up 
to seven or eight passages, foci with the appearance of fig. 3.3a appeared in 
post confluent cultures of cells in 100mm dishes. Foci were often visible to 
the naked eye.
Morphology of the cell lines 
The appearance of the original parent cultures of trabecular bone cells 
viewed under phase contrast microscopy is shown in figure 3.3c, displaying 
the characteristic fibroblastic morphology and heterogeneity of these cells. 
The morphology of cell line Bath Osteoblast Prototype (BOP) 26 is shown in 
figure 3.3d.
Expansion of immortalised cell lines 
The capacity of SV40 transfected cells for rapid growth is illustrated in 
figure 3.4. These graphs demonstrate the large number of cells that could 
be obtained assuming that all harvested cells were replated at each 
passage. For example, BOP 15 seeded at 2 x 104 cells in one well of a 6 
well plate could be expanded to 2.7 x 1010 cells in 40 days.
The growth curve (Fig. 3.5) shows that BOP 26 has a cell division time of 
30h compared with 26h for MG-63 and 120h for primary cultures of 
trabecular bone cells.
Alkaline phosphatase activity 
The expression of the enzyme alkaline phosphatase by SV40 
immortalised osteoblasts is shown in table 3.3. A range of activities was 
observed, cell lines 26, 31 and 33 for example having much lower activity 
than cell lines 19, 71 and 72. Treatment with 10'8M 1,25D enhanced ALP 
activity in cell lines 16, 31, and 62, but had no effect on cell lines 7, 33 and 
72.
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Growth of clonal cell lines 
Two cell lines (BOP 26 and 37) were chosen for cloning by limiting dilution 
as they closely resembled the parent cultures with respect to the osteoblast 
phenotype (described in chapter 4). After two rounds of limiting dilution 
cloning many cell lines entered crisis and senesced. 3 cell lines from BOP 
37 and five from BOP 26 grew sufficiently to be cryopreserved. After thawing 
of cell lines 37WW3, 37WW5 and 37WW8, 26A4, 26A5 and 26A12 only the 
two clonal cell lines 37WW3 and 37WW8 provided sufficient numbers of 
cells for characterisation of ALP activity. As displayed in table 3.4 the clonal 
cell lines expressed very high levels of ALP activity and were also capable 
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Fig. 3.1 (a) Log-io Kb versus distance moved through the gel for Eco Rl
and Hind III digests of X  DNA subjected to electrophoresis, (b) Agarose gel 
of the DNA digests. Lane A, Hind III digest of X  DNA; lanes B-F, digests of 
pX-8 , B: Hpa II and Bam HI, C: Pst I, D: Xho I, E: Bam HI and Xho I, F: EcoRI. 







Eco Rl 5 .4
2.6
6.2
Bam HI + Xho I 5
2.9
5
Pst I 1 .9
1.2
3





Table 3.2 Restriction digest fragments of the pX-8  vector, obtained by 
incubation of vector DNA with the appropriate enzyme, followed by gel 
electrophoresis as described in methods. Fragment size was calculated by 




LATEH p a l l
PX 8 = X h o lE c o H I
H p a l l
B g l l
SV40 ori
AmpR






P s t l P s t l
P V u l l / R I
B a m H I  y
Fig. 3.2 Restriction map of the pX- 8  vector with sizes of the SV-40 early 
and late regions indicated. (Modified from Fromm and Berg, 1982).
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Fig. 3.3. Morphology of parent and SV40-transfected cells. Primary cultures 
of human osteoblast-like cells were transfected with pX-8  and maintained in 
complete medium, (a) Focus formation by transfected cells. Discrete foci of 
rapidly dividing cells were observed in all transfected cultures (arrowed).
(b) A focus of mitotic cells in a culture of cell line BOP 4 at passage 4 
(arrowed), (c) The characteristic heterogeneous morphology of parent 
cultures of ostoblasts; (d) The morphology of cell line BOP 26, the cells were 
polygonal and presented a more homogeneous appearance than primary 
cultures. Magnification X 100.
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Fig. 3.4 The rapid expansion of four cell lines maintained in continuous 
culture. Each point on the graph represents one passage. Cell number was 
calculated assuming all harvested cells had been replated at each passage.
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Fig. 3.5 Growth curves for the immortalised osteoblast-like cell line BOP 
26, cells of the human osteosarcoma line MG-63 and primary cultures of 
human osteoblasts (HObs). Cell counts were performed on trypsinised cell 





BOP Control 1.25D T/C Time with
1.25D (h).
4 0.081 >0.093 - 96
7 0.013 0 .0 0 1 2 1.1 96
1 2 0.052 >0.093 - 96
16 0.004 0.014 3.5 96
18 0.015 0.023 1.5 96
19 >0 .0 2 >0 .0 2 - 72
26 0.008 0.005 0 .6 72
31 0.005 0.023 4.6 72
33 0 .0 0 2 0 .0 0 2 1 .0 72
37 0.065 0.057 0.9 72
62 0 .0 0 2 0.032 16 72
70 0.027 0.040 1.5 72
71 >0.08 0.050 - 72
72 0.042 0.039 0.9 72
74 0.040 >0.067 72
Table 3.3 Alkaline phosphatase activity in immortalised cell lines. Cells 
were seeded into single microtitre wells and allowed to settle for 24h. Cells 
were then treated with 10_8M 1,25D for the length of time indicated and cell 
layers were assayed for ALP activity in situ as described in methods.




Clone Control 1.25D JJQ.
37WW3 4.81 ±0.92 7.68 ±0.55 1.6
37WW8 9.07 ±0.52 16.49 ±0.92 1.8
Table 3.4 Alkaline phosphatase activity in clonal cell lines. Cells were 
treated with 1,25D for 48h as described in methods. ALP and total protein 
assays were performed on cell layers. Data are shown ±  standard error of 
the mean (SEM), n=4.
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3.4 DISCUSSION
The calcium phosphate/DNA coprecipitation technique has been used to 
transfect a variety of cell types such as human juxtaglomerular cells (Pinet et 
al, 1985), neonatal rat Schwann cells (Tennekoon etal, 1987) and human 
fibroblasts (Mayne etal, 1986). Primary cultures of human trabecular bone- 
derived cells were readily transformed by origin defective SV40 DNA using 
the calcium phosphate method. The vector induced a loss of contact 
inhibition and proved to be potent at inducing the cells to undergo repeated 
mitotic divisions. The foci of rapidly dividing cells observed in transfected 
cultures also appeared in confluent cell lines that had been maintained in 
vitro for a number of passages (Fig. 3.1) displaying that the initial loss of 
contact inhibition of growth was sustained for many generations.
Comparison of the growth curves for human osteoblasts and immortalised 
BOP cells demonstrates the rapid proliferation rate of the latter (Fig. 3.5). 
Primary cultures divided in 125h whereas BOP cells took only 30h to divide, 
slightly more than the cell cycle time for human osteosarcoma cells (MG-63) 
which completed division in 26h. This is in contrast with the observations of 
Huschtscha and Holliday (1983). These authors transfected human foetal 
lung fibroblasts (MRC-5) with wild-type SV40 virus strains and obtained two 
immortalised cell lines. The parent cultures, at an early passage, divided in 
18-21 h whereas the immortalised cells took 38h to divide. Human bone 
marrow stromal cells transfected with a recombinant SV40-adenovirus 
vector divided in 30h (Aizawa etal, 1991). Cells of different origin behave 
differently following transfection and these differences may be observed 
irrespective of the vector used, for example human juxtaglomerular cells 
transfected with origin defective SV40 were slow to divide and were 
subcultured once a month (Pinet etal, 1985).
Immortalisation of cells with SV40 is clearly a useful procedure for 
obtaining large numbers of cells derived from parent cultures. From an
initial population of 9.5X106 trabecular bone cells a total of 74 cell lines 
were obtained each capable of providing over 1010 cells. The mechanism 
by which SV40 effects this dramatic transformation is unknown but 
expression of the large tumour antigen has been shown to be essential for 
the induction of anchorage independent growth of transfected cells (Mayne 
etal, 1986; Radna etal, 1989). Expression of the large T antigen by BOP 
cells is demonstrated in chapter 4.
Cell lines transfected with SV40 typically enter a period termed "crisis'' 
after a limited number of divisions; cells are shed into the medium and 
remaining cells senesce. Some cells may survive and emerge as stable, 
post-crisis immortalised lines but the frequency of such lines is low (Oshima 
etal, 1977; Huschtscha and Holliday, 1983). When BOP cells were 
subjected to two rounds of limiting dilution cloning, in order to obtain clonal 
cell lines, many clones failed to divide and large, irregular, senescent cells 
were observed. Of six clonal lines that were cryopreserved and revived only 
two survived and grew in sufficient numbers for the assay of alkaline 
phosphatase activity. These may represent stable post-crisis cell lines.
Use of a dominant selectable marker has been reported to improve the 
frequency of establishing a stable, immortalised cell-line. Mayne eta l,
(1986) employed an origin-defective SV40 construct encoding T antigen 
and the bacterial gene xanthine-guanine phosphoribosyl transferase (gpt). 
Human fibroblasts transfected with this plasmid were able to grow in 
medium containing the metabolic inhibitors mycophenolic acid and 
aminopterin. Other workers have used the neomycin resistance gene as a 
selectable marker (Heath eta l, 1989; Kellerman eta l, 1990). Use of a 
selectable marker, however, does not prevent the crisis stage of pre­
immortalised cells from occurring (Mayne etal, 1986; Keeting etal, 1992).
Primary cultures of trabecular bone cells express both constitutive and 
1,25D-inducible alkaline phosphatase activity (Beresford, Gallagher and
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Russell, 1986). This enzyme is not osteoblast-specific but is a characteristic 
of the cell type and is widely used as a marker of the osteoblast phenotype. 
Human osteoblast-like cells transfected with SV40 DNA produced the 
enzyme alkaline phosphatase and activity of the enzyme was enhanced by 
1,25D. The two clonal cell lines 37WW3 and 37WW8 also expressed very 
high levels of the enzyme and responded to 1,25D by an enhancement of 
enzyme activity.
Large numbers of rapidly dividing cells were obtained following 
transfection of primary cultures of human osteoblast-like cells with SV40 
DNA. The cells retained the capacity to express an enzyme characteristic of 
the parent cultures and to respond to the osteotropic hormone 1,25D. The 
cell lines had a limited growth potential and are likely to represent the "pre- 
immortalised" state described by Huschtscha and Holliday (1983). Two cell 







Rapidly dividing BOP cells were characterised for established markers of 
the osteoblast phenotype. Thirteen cell lines expressed alkaline 
phosphatase activity which was enhanced by 1,25D and the cells 
responded to 1,25D by production of the mineralised tissue-specific protein 
osteocalcin. BOP cells displayed the ability to produce osteonectin and 
bone sialoprotein constitutively and production of these proteins was 
unaffected by 1,25D. The cells secreted thrombospondin and 1,25D elicited 
variable responses with respect to production of this protein. The cells 
displayed the ability to mineralise in vitro as visualised by both von Kossa 
and Alizerin Red staining. mRNA for Type I Collagen was detected by 
Northern blotting in seven cell lines. Two cell lines produced PGE2 in 
response to IL-1. Incorporation of SV40 DNA was confirmed by Southern 
blotting and expression of large T antigen was demonstrated by 
immunofluorescence. The data demonstrate that immortalised cell lines 
derived by transfection of primary cultures of osteoblasts with SV40 DNA are 
capable of retaining the full phenotype of the parent cells.
4.1 INTRODUCTION
An essential requirement of any model used for the study of osteoblast 
function in vitro is the expression of the phenotypic characteristics of 
osteoblasts in vivo. A variety of current models are described in chapter 1 
(Table 1.1). Primary cultures of human osteoblasts derived as outgrowths 
from trabecular bone have been extensively characterised with respect to 
extracellular matrix production and responsiveness to calciotropic 
hormones. The cells express high levels of the bone-liver-kidney isoenzyme 
alkaline phosphatase and enzyme activity is enhanced by 1,25D (Beresford, 
Gallagher and Russell, 1986). The cells produce predominantly type I 
collagen but a small percentage of the total collagen produced is type III
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which may indicate contamination of the cultures by fibroblasts (Aufmkolk, 
Hauschka and Schwartz, 1985). Cells maintained in medium supplemented 
with p glycerophosphate, which serves as a substrate for alkaline 
phosphatase, may produce a thick, extracellular, mineralised matrix in vitro 
(Gehron Robey and Termine, 1985). Production of bony nodules by human 
bone cells transplanted intramuscularly into mice has also been reported 
although some strains of cells did not display in vivo osteogenic activity 
(Yamamoto, Ecarot and Glorieux, 1991).
A characteristic of many osteoblast model systems from different sources is 
a PTH responsive adenylate cyclase. PTH also stimulates the proliferation 
of human bone-derived cells and enhances secretion of PGE2 (MacDonald, 
Gallagher and Russell, 1986; MacDonald etal, 1984). Osteoblasts also 
produce PGE2 in response to IL-1 (Gowen, 1988).
The most specific marker available for the identification of osteoblast-like 
cells is the noncollagenous matrix protein osteocalcin. Primary cultures of 
trabecular bone cells produce low or undetectable levels of osteocalcin 
which are enhanced by 1.25D (Aufmkolk, Hauschka and Schwartz, 1985; 
Yamamoto, Ecarot and Glorieux, 1991). Human osteoblast-like cells also 
secrete the matrix proteins osteonectin, bone proteoglycan and 
thrombospondin (Gehron Robey and Termine, 1985; Gehron Robey etal, 
1989).
The ability of cell lines obtained by transfection of primary cultures with 
SV40 DNA to retain the full osteoblastic phenotype was assessed. BOP 
cells were characterised for the production of noncollagenous matrix 
proteins, expression of type I collagen mRNA, synthesis of PGE2 and 
production of a mineralised matrix.
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4.2 METHODS
Cell lines were incubated in the presence and absence of 1,25D and 
characterised for alkaline phosphatase expression and production of 
osteocalcin as described in chapter 2 (general methods). Production of 
SV40 large T antigens by transfected cells was assessed by 
immunofluorescence (chapter 2 ).
Production of a mineralised matrix 
Cells were seeded at 104 per well of multichamber slides and maintained in 
complete medium for 3-4 days. Cells were then incubated for a further 7 days 
in defined medium + L-ascorbate + vitamin Ki in the presence and absence 
of 5mM p glycerophosphate (pGP) ±  10_8M 1,25D. The glycerophosphate 
serves as an organic substrate for the enzyme alkaline phosphatase. 
Following incubation cell layers were washed in phosphate buffered saline 
(PBS), fixed in 80% ethanol, and stained for phosphate by the von Kossa 
method and for calcium deposition using Alizerin Red S.
a). von Kossa stain 
The von Kossa stain is a well established method for visualising mineral 
deposition in vitro. Fixed cells are covered with silver nitrate and exposed to 
ultraviolet light (uv). The uv light causes the silver to cross-link with 
hydroxyapatite in the extracellular matrix forming a black deposit of silver 
phosphate. The staining procedure is as follows:
(i). Wash fixed sections twice for 1 0 min in distilled water.
(ii). Add freshly made up 1% (w/v) silver nitrate in distilled water and
expose to uv light for 30min.
(iii). Rinse in distilled water.
(iv). Rinse in 5% (w/v) sodium thiosulphite for 30s.
(v). Wash in tap water for 10min.
(vi). Wash in distilled water for 10min.
(vii). Wash in 70% ethanol for 10min.
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(viii). Wash in absolute ethanol for 10min.
(ix). Clear in cedar wood oil.
b). Alizerin Red-S stain
Alizerin sodium sulphonate is a salt that binds metal ions, but preferentially 
binds Ca2+ ions.
(i). Wash fixed slides in 50% ethanol.
(ii). Wash in distilled water.
(iii). Cover with 2% (w/v) alizerin red in distilled water pH 4.1 to 4.3 (adjust 
pH with dilute NH4 (OH)2> for 30s-5min.
(iv). Rinse with distilled water twice.
(v). Mount in cedar wood oil.
Prostaglandin E^production
Cells, in 16mm wells, were incubated in the presence and absence of 
1 0 U/ml rhlL-1afor 48h in MEM+3% FCS. Conditioned media from these 
cultures were stored at -20°C for the subsequent determination of PGE2 
production. PGE2 production was measured by specific radioimmunoassay, 
using rabbit antisera. The specificity of the antisera is shown in table 4.1.
Standards of 1.25, 0.625, 0.313, 0.156, 0.078, 0.039, 0 .0 2  and 0 .0 1 ng/1 0 0^  
PGE2 were prepared in assay buffer (0 .1% w/v gelatin in 0.01  M Trizma base, 
0.14M NaCI, pH 7.4). 100|xl of sample or standard were transferred to LP3 
tubes and 100^1 of both antiserum and tritiated PGE2 added. A medium blank 
was included and also total counts, maximum binding (1 0 0 |il each of buffer, 
antibody and tracer) and non-specific binding (100^1 tracer, 150^1 buffer) as 
with the osteocalcin assay (described in chapter 2). Tubes were vortexed 
and incubated at 4°C overnight.
600mg of Norit A charcoal + 125mg Dextran T70 were mixed with 1 0 0 ml 
assay buffer and left on a magnetic stirrer at 4°C until the charcoal was
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Prostaglandin E2 1 0 0 .0  %
Prostaglandin E1 1 0 .0  %
Prostaglandin F ia 3.3 %
Prostaglandin B1 3.0 %
Prostaglandin D2 0.01 %
Prostaglandin A1 0 .01 %
Prostaglandin A2 0 .01 %
Prostaglandin F2« 0 .01 %
13,14-Dihydro-6-keto-prostaglandin F ia 0 .01 %
6 -Keto-prostaglandin F ia 0 .01 %
Thromboxane B2 0 .01 %
13,14-Dihydro-15-keto-prostaglandin F2a 0 .01 %
Table 4.1 Comparative cross-reactions of the antiserum raised in rabbits 
against prostaglandin E2 .
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completely in suspension. The charcoal is used to adsorb any unbound 
tracer. On day 2  of the assay 200jil of charcoal were added to each tube, 
tubes were vortexed and then centrifuged at 2 ,0 0 0 g for 15min at 4°C. 200|xl 
of the clear supernatant were decanted into scintillation vials, 500^1 of 
scintillant added and the amount of incorporated radioactivity monitored 
using a Rackbeta scintillation counter. A graph of concentration vs B/Bo was 
plotted as for the osteocalcin assay and results extrapolated. A typical 
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Concentration of PGE2 (ng/100 ^l)
Fig. 4.1 A typical standard curve forth© prostaglandin assay
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Noncollagenous matrix proteins 
Osteocalcin was measured as described in Chapter 2. Thrombospondin, 
osteonectin and bone sialoprotein in the same conditioned media were 
detected by specific radioimmunoassay. These assays were performed by 
Chantal Chenu and co-workers at INSERM, Lyon, France.
Expression of type I collagen mRNA 
RNA was isolated from confluent, unstimulated cells as described in 
chapter 2. Expression of mRNA for type I collagen was assessed by 
Northern blotting.
For Northern blot analysis 10^g per sample of RNA were dissolved in 10jaI 
of loading buffer prepared as follows:
60jj.I 10XMOPS, 300|il formamide, 100^ .1 formaldehyde, 140^1 DEPC water.
1 jxl of RNA gel loading dye was added to each sample.
RNA was electrophoresed in a denaturing gel of 1% (w/v) agarose with 
14% (v/v) formaldehyde in 1X MOPS buffer, at 30mAmps for at least 7h.
RNA was transferred to a Hybond-N+ filter by overnight blotting with 20X 
SSC as the transfer buffer. Filters were fixed for five minutes in 50mM 
sodium hydroxide and stored wrapped in cling film at <4°C. Filters were 
hybridised as described in chapter 2, with a cDNA probe for a-j pro-collagen 
(type I).
Incorporation of pX-8  
The incorporation of the SV40 vector into host cell DNA was confirmed by 
Southern blotting.
a). DNA isolation 
Chromosomal DNA was isolated from cells by a salting-out procedure 
(Miller, Dykes and Polesky, 1988). Cell pellets were resuspended in 3ml 
nuclei lysis buffer (1 0 mM Tris, 400mM NaCI, 2mM Na2EDTA, pH 8.2) and 
protease K and 1 00m.I of 20% SDS added. After a 3h incubation at 55°C 1ml 
of 6 M NaCI was added and the suspension shaken vigorously. Tubes were
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centrifuged for 25min at 2,000g. The supernatant was transferred to a clean 
tube, 8 ml of absolute ethanol added, and the contents mixed by inversion. 
Precipitated DNA was removed using a sealed pasteur pipette and 
dissolved in Tris-EDTA.
b) Southern blot analysis
Restriction endonuclease digests of BOP cell DNA were carried out with 
the enzymes Xba I and Bst XI. There are no restriction sites for Xba I on the 
pX-8  vector but there is one Bst XI site in the SV40 early region at base pair 
4770. COS cell DNA was included as a positive control as these cells 
constitutively express SV40 early region genes. 10^g of DNA were diluted 
in water to make a final volume of 25^ 1, V I of enzyme and 2jj.I of appropriate 
buffer were added. Xba I digests were incubated at 37°C and Bst XI digests 
were incubated at 45°C overnight.
Southern blots of DNA digests were performed by overnight electrophoresis 
in 0.8% agarose gels with 1X Tris acetate as the running buffer, x Hind 
digests of x DNA were used as molecular size markers. The gel was then 
placed in 0.25M HCI until the dyes changed colour (bromophenol blue to 
green, xylene cyanol to yellow) and left for a further 10min. DNA was 
transferred to Hybond-N+ filters by alkali blotting, with 50mM NaOH as the 
transfer buffer. Filters were prehybridised in a solution of 6 X SSPE, 5X 
Denhardt’s, 5% dextran sulphate, 1% SDS for 4h at 65°C and hybridised with 
a 3Kb fragment of SV-40 early DNA excised from the pX-8  vector. Filters 
were washed twice in 2 X SSPE, 0.5% SDS for 15min at 65°C and washed 
once in 0 .2 % SSPE, 0.5% SDS for 10min at 65°C. Hybridised, washed filters 
were subjected to autoradiography.
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4.3 RESULTS
Alkaline phosphatase expression 
The constitutive and 1,25D-inducible alkaline phosphatase activity of 
SV40 immortalised osteoblasts is shown in table 4.2. The cell lines 
exhibited a range of enzyme activities and differential responses to 1,25D. 
For example, in experiment 1 cell lines 7, 12, 62 and 72 had almost 
undetectable ALP activity and were unaffected by treatment with 1,25D. Cell 
lines 15 and 26 had higher levels of ALP which were enhanced by 1,25D. In 
experiment 2  enzyme activity for all cell lines was very low compared with 
the other 3 experiments and again great variation between cell lines with 
respect to both constitutive ALP and 1,25D responsiveness was observed. 
The ALP activity of the parent, nontransfected trabecular bone cell cultures 
(HObs) was enhanced almost twofold by 1,25D (Table 4.2b). Cell line BOP 
37 maintained high levels of ALP and responsiveness to 1,25D in all 4 
experiments. BOP 26 also exhibited high ALP activity. By comparison, BOP 
7 displayed lower levels of ALP expression.
98
Table 4.2 The following two pages show data for alkaline phosphatase 
expression by BOP cells assayed in four experiments. Cells were incubated 
in defined medium ±  1,25D (10_8 M) for 48h. Cell layers were freed by 
scraping with a rubber policeman and assayed for ALP activity as described 
in Chapter 2 . (a) and (b), alkaline phosphatase activity in 13 BOP cell lines
and parent cultures of osteoblasts (HObs) (^moles/min/mg total protein), (c)
Si
and (d), ALP activity in s£veh cell lines. SEMs are shown in (d). T/C is the 














































.CqoIlq] 1.25D. I E
0.0150 0.0147 1 .0
0.0230 0.1230 5.4
0 .0 2 1 0 0.0095 0.4
0 .0 0 0 2 0.0080 40.0
0 .0 1 0 0 0.0045 0.5
0.2780 0.0340 1 .2
0.0068 0.0109 0 .6
0.0023 0.0843 36.6
0.0295 0.0541 1 .8
0.0322 0.0081 0.3
0.0278 0.0822 3.0
0.0446 0.0350 0 .8






BOP Control 1.25D HQ
7 0.570 0.863 1.5
1 2 0.660 >1.5 -
26 >1.5 >1.5 -
31 >1.5 >1.5 -
33 0.11 0.175 1 .6
37 0.715 1.5 2.1
















d). Experiment 4, n=3.
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Production of noncollaaenous matrix proteins
The production of osteocalcin by BOP cells is shown in figure 4.2 and a 
separate experiment is shown in table 4.3. With the exception of BOP 31 
which produced a very low level of osteocalcin (0.1ng/ml) constitutively, the 
cell lines produced osteocalcin only in response to 1,25D. The cell lines 
produced variable amounts of osteocalcin; for example lower levels were 
produced by BOP 7 than by BOP 26 and 37.
The cell lines all produced similar levels of bone sialoprotein (BSP) which 
were not affected by treatment with 1,25D (Fig. 4.3). All the cell lines 
produced osteonectin again with very little variation between cell lines or 
response to 1,25D (Fig 4.4). With respect to thrombospondin production 
(Fig. 4.5) a much greater variation was observed between different cell lines; 
for example, BOP 7 produced very low levels of thrombospondin (11 ng/ml) 
compared with BOP 37 (210ng/ml) and BOP 19 (120ng/ml). 1,25D 
enhanced thrombospondin secretion in cell lines 26, 61, 72 and 74, but 
reduced production of the protein in lines 19, 37, 71 and 31. The effects of 
1,25D on thrombospondin release were not consistent with BOP number but 
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Fig. 4.2 Osteocalcin production by BOP cells, mean value for 1.25D 
treated BOP cells is 4.2 ± 0 . 6  ng/ml. Cells were seeded into 30mm wells, 
allowed to settle for 24h, and treated with ethanol vehicle or 10'8M 1,25D for 
48h. Conditioned media were assayed for osteocalcin using a specific 













72 0 6 .2
74 0 0.7
Table 4.3 Osteocalcin production (ng/ml) by BOP cells. Cells were treated 
for 48h with 1,25D (10 '8M) and osteocalcin in conditioned media measured 
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Fig. 4.3 Bone sialoprotein production by BOP cells. Conditioned media 
were prepared as described in the legend to Fig. 4.2 and assayed for bone 
sialoprotein by radioimmunoassay. Mean values for control and 1,25D 
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Fig. 4.4 Osteonectin production by BOP cells. Conditioned media were 
prepared as described in the legend to Fig. 4.2 and assayed for osteonectin 
by radioimmunoassay. Mean values for control and 1,25D treated BOP cells 
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Fig. 4.5 Thrombospondin production by BOP cells. Conditioned media 
were prepared as described in the legend to Fig. 4.2 and assayed for 
thrombospondin by radioimmunoassay. Mean values for control and 1.25D 
treated BOP cells are 60.8 ±15.7 and 58.9 ± 4.42ng/ml respectively.
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Mineralisation in vitro 
The ability of the immortalised cell lines to mineralise in vitro was assessd 
by the von Kossa stain which demonstrates phosphate deposition, and the 
Alizerin Red S stain which binds Ca2+ ions. The amount of staining present 
in fixed cells is shown in table 4.4, the degree of staining observed was 
recorded as absent (-), weakly present (+/-), or present to varying intensities 
(+). In experiment 1 (Table 4.4a) no von Kossa staining was observed in 
control cells but varying amounts of phosphate deposits were present in 
cells that had been incubated with p glycerophosphate. In experiment 2 no 
von Kossa staining was observed in control or 1,25D treated cells; weak 
reactivity occurred in p glycerophosphate treated cells of BOP 26 and 37 and 
staining was enhanced by 1,25D in these cell lines. Other cell lines 
produced a positive von Kossa reaction only when both p GP and 1,25D 
were present. Spearman rank tests demonstrated no correlation between 
the intensity of the von Kossa stain and the levels of ALP, osteocalcin, bone 
sialoprotein, osteonectin or thrombospondin. The staining pattern of BOP 37 
cells is shown in figure 4.6. Cell lines displayed varying Alizerin Red 
reactivities (Table 4.4b), calcium deposition was enhanced by addition of p 
glycerophosphate to the medium but not dramatically affected by 1,25D. 
Prostaglandin production 
BOP cells failed to produce PGE2 constitutively and only two cell lines,
BOP 26 and 62 secreted PGE2 in response to interleukin 1 (Table 4.5). 
Expression of type I collagen mRNA 
Cell lines 7 , 1 2 , 26, 31, 33, 37 (at passage (p) 9 and 19) and 70 all 
expressed mRNA for type I collagen as shown in figure 4.7.
Incorporation of vector DNA and expression of SV40 T antigens 
The seven cell lines listed above expressed SV40 T antigens, 
immunolocalisation of the antigens in the nuclei of cell lines 31 and 37 is 
shown in figure 4.8. Southern blot analysis demonstrated the presence of
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SV40 DNA in six cell lines tested. There are no sites recognised by the 
restriction endonuclease Xba I in the pX-8  vector and digestion of BOP cell 
DNA with this enzyme resulted in one band appearing on the Southern blot 
for each of six cell lines. The exception was BOP 31 which gave two bands, 
suggesting that this cell line was derived from cells which had incorporated 
the vector into two distinct sites of host DNA. The enzyme Bst XI cuts the pX- 
8  vector approximately mid-way along the 3Kb segment used to hybridise 
the Southern blot. Digestion of BOP cell DNA with Bst XI yielded at least two 
bands (Fig. 4.9).
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Experiment 1 Experiment 2
POP PSP PSE BGP + 1.25D
4 weak+ - weak+
7 +++ - -
12 +++ - +++
15 ++ - -
19 + - -
26 ++ weak+ ++
31 weak+ - -
37 ++ weak+ ++++
62 +++ - +
71 weak+ - +
a). von Kossa staining reaction of BOP cells
Control 1.25D 1.25PtBGE
weak + ++
+ +  + + +
+ /- + /- + /- + +
+ + + + + +  + +
+++  +++
+/- + + + +  +++
b). Alizerin red S.
Table 4.4 Mineralisation in vitro by BOP cell lines. Cells were incubated in 
wells of multichamber slides and treated with 1,25D (10‘8M) + 5mM p 
glycerophosphate (pGP) for seven days. Fixed preparations were stained by 
the von Kossa method (a) or with Alizerin Red S (b). Staining was absent (-) 











Fig 4.6 von Kossa staining reaction in BOP 37. (a) Cells incubated with p 















Table 4.5 Production of PGE2 (ng/ml) by BOP cells. Cells were incubated 
in the presence and absence of 10 U/ml rh IL-1<xfor 48h in MEM + 3% FCS. 
PGE2 in conditioned media was measured by radioimmunoassay.
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Fig. 4.7 Type I collagen mRNA expression in BOP cells. RNA was 
prepared from confluent monolayers of cells and subjected to gel 
electrophoresis and Northern blotting Filters were hybridised with a cDNA 
probe for a-j pro-collagen then stripped and reprobed for human p actin as 
described in methods.
(b)
Fig. 4.8 Expression of large and small SV40 T antigens in transfected BOP 
cells. Cells were seeded onto poly-L-lysine treated glass multispot slides 
and allowed to settle overnight. Preparations were fixed in acetone and 
stained by indirect immunofluorescence as described in chapter 2. (a) BOP 
31, (b) BOP 37. X100.
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Fig. 4.9 Incorporation of the pX-8 plasmid into transfected cells. DNA was 
prepared from BOP cells as described in methods and subjected to 
restriction endonuclease digestion, gel electrophoresis and Southern 
blotting. Molecular size is indicated on the left hand side. X=Xba I, B=Bst XI.
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4.4 DISCUSSION
Characterisation of immortalised BOP cells demonstrated that the cell lines 
were capable of expressing the phenotype of mature osteoblasts. The cell 
lines expressed mRNA for type I collagen, the major constituent of bone 
extracellular matrix, and secreted bone-associated noncollagenous 
proteins. In addition, cells were responsive to the major calciotropic 
hormone 1,25D. Only two cell lines produced prostaglandin E2 in response 
to IL-1 which may reflect the heterogeneity of the parent cultures.
Expression of the bone isoenzyme alkaline phosphatase was extremely 
variable when assayed at different time points in both control and 1,25D 
treated cells. A similar variation has been reported for the murine clonal 
osteoblastic cell line MC3T3-E1, these cells display low alkaline 
phosphatase activity when in the logarithmic phase of growth and 1 0 0  fold 
higher levels at confluence (Sudo et al, 1983). Primary cultures of human 
osteoblasts contain subpopulations of alkaline phosphatase positive cells 
with strong, weak or undetectable activity (Matsuyama, Lau and Wergedal, 
1990). This variation has been attributed to the asynchronous nature of the 
cultures and to cell cycle changes. Fedarko et al (1990) obtained 
synchronous populations of human osteoblasts by a thymidine-aphidicolin 
double blockade method and observed a drop in the levels of cell- 
associated ALP activity during mitosis. ALP activity returned slowly during 
G1 and reached a peak during S phase. When the constitutive ALP activity 
of BOP 26 was assayed every two days over a period of nine days a small 
increase in activity was observed as cells attained confluence (Bell, Williams 
and Gowen, unpublished observations). The levels of ALP activity in BOP 
cells were higher than are commonly observed with cells of the human 
osteosarcoma cell line MG-63 which express very little ALP activity when 
treated under the same conditions (Clover, personal communication).
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BOP cells produced osteocalcin in response to 1,25D displaying their 
ability to differentiate when incubated in the presence of the hormone, in 
common with primary cultures of osteoblasts. The pattern of 
noncollagenous protein synthesis in cell lines 37 and 26 was considered to 
most closely resemble the behaviour of normal trabecular bone cells 
(Delmas, personal communication). BOP 7 produced low levels of both ALP 
and osteocalcin but high levels of bone sialoprotein. This cell line provides 
an interesting negative comparison and may represent less well 
differentiated osteoblasts that were present in the parent cultures. The cell 
lines displayed differential responses to 1.25D with respect to 
thrombospondin production. The precise role of this protein is unknown but 
it has been demonstrated to promote the attachment, but not spreading, of 
osteoblasts in vitro (Gehron Robey etal, 1989). Similarly, bone sialoprotein 
has cell attachment activity whereas osteonectin lacks an RGD sequence 
but may be important in regulating mineralisation.
The variation observed in von Kossa staining reactivities is likely to relate 
to changes in the activity of alkaline phosphatase. The von Kossa stain is 
not a specific monitor of bone matrix production, p glycerophosphate added 
to the culture medium provides an organic substrate for alkaline 
phosphatase resulting in the extracellular deposition of phosphate which is 
visualised by conversion to silver phosphate in the von Kossa reaction.
Cells expressing high levels of alkaline phosphatase would be expected to 
demonstrate a positive reaction. Alizerin Red S is a salt that binds calcium 
and demonstrates that BOP cells produce a calcium phase in vitro that is 
likely to be calcium phosphate.
The rapid growth of BOP cells described in chapter 3 is attributable to the 
production of SV40 T antigen. When early region cRNA encoding T antigen 
is injected into epithelioid cells production of the viral protein induces 
chromatin replication and mitosis (Graessmann and Graessmann, 1976). T
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antigen is able to catalyse the hydrolysis of ATP to ADP+Pj and binds DNA. 
The protein may cause the unwinding of portions of duplex DNA, allowing 
polymerases to bind and initiate replication (Tjian and Robbins, 1979).
Immortalised cell lines derived by transfection of primary cultures with 
SV40 DNA provide a self-renewing population of cells that retain the 
characteristics of parent cultures. BOP cells expressed all the hallmarks of 
mature osteoblasts. Variation between cell lines with respect to production 
of noncollagenous proteins, prostaglandins and expression of alkaline 
phosphatase may reflect the heterogeneity of the parent cells. Two cell 
lines, BOP 26 and 37, were considered to most closely resemble primary 
trabecular bone cells; in contrast BOP 7 was less well differentiated and may 
represent an osteoblast precursor.
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CHAPTER 5





Locally-produced cytokines may be important regulators of bone 
remodelling; IL-1 and TNF for example stimulate both osteoclastic resorption 
and osteoblast proliferation. Human osteoblast-like cells derived from 
trabecular bone are capable of producing the cytokines IL-1, IL-6 , TNF and 
TGFp. Seven BOP cell lines were characterised for their ability to produce 
the cytokines IL-1, TNF and IL-6 . The effects of oestradiol (E2) on cytokine 
release and on the expression of mRNA for TGFp were also assessed.
All seven cell lines produced IL-1 in response to TNF; constitutive levels of 
IL-1 were very low and were not affected by treatment with 17p-oestradiol. 
Treatment with IL-1 a enhanced expression of mRNA for IL-1 p in six cell lines 
tested. Seven cell lines released bioactive IL-6  and production of this 
cytokine was enhanced by IL-1 and TNF but unaffected by E2 . The cell lines 
released high levels of immunoreactive TNF constitutively, production of 
TNF was not affected by IL-1 and was slightly enhanced by treatment with E2 
in one cell line only. Constitutive expression of TGFp mRNA was low in six 
cell lines tested and was not affected by treatment with E2 .
The production of IL-1 and responsiveness of the cells to IL-1 and TNF 
were similar to the results previously observed with primary cultures. High, 
aberrant production of TNF may be a result of the SV40-induced 
transformation process.
5.1 INTRODUCTION
Immune-cell derived cytokines such as IL-1 and TNF are potent stimulators 
of osteoclastic resorption and may be important physiologic regulators of 
bone turnover. Together with a variety of other growth factors they are 
produced locally by cells in the bone microenvironment and may act in a 
paracrine or autocrine fashion to affect bone cell function. IL-1 and TNF 
have anabolic effects on bone by stimulating the proliferation of human
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osteoblasts (Gowen, 1992). The proliferative effect of TNF was not seen in 
the absence of serum, suggesting that additional growth factors are 
required. This enhanced proliferative activity is accompanied by a reduction 
of differentiated function; IL-1 inhibits alkaline phosphatase activity and 
antagonises the production of osteocalcin induced by 1,25D (Evans,
Bunning and Russell, 1990). Similarly TNF inhibits basal and 1,25D 
enhanced alkaline phosphatase activity and osteocalcin release and, like 
IL-1, stimulates the release of prostaglandins (Gowen, MacDonald and 
Russell, 1988). These two cytokines, in conjunction with other growth 
factors, may be important regulators of osteoblast proliferation prior to a new 
round of bone formation at the Howship's lacuna.
Interleukin 6  is a cytokine with similar activities to IL-1, most notably 
induction of the acute phase response and induction of fever. IL-6  has been 
reported to either enhance osteoclastic resorption or have no effect and this 
variation may result from the different models used (chapter 1 , 1 .6 .2 (a)). 
Reports of the effects of IL-6  on osteoblast function also vary depending on 
the model system studied. Fang and Hahn (1991) report a dose-dependent 
increase of tritiated thymidine incorporation induced by IL-6  in cells of the rat 
osteosarcoma cell line UMR-106-01. IL-6  also increased prostaglandin 
release, decreased the percentage of collagen synthesised but had no effect 
on alkaline phosphatase activity in this model. In human osteoblast-like 
cells IL-6  had no effect on DNA synthesis or on the expression of mRNA for 
type I collagen (Linkhart etal, 1991). IL-6  failed to affect IL-1 induced 
proliferation of either human osteoblasts or the clonal rat osteosarcoma cells 
ROS 17/2.8, and did not affect basal or 1.25D induced alkaline phosphatase 
activity in these cell types. Neither human osteoblasts nor ROS 17/2.8 cells 
produced PGE2 in response to IL-6  and IL-6  did not affect IL-1-induced 
PGE2 release (Littlewood etal, 1991a). The osteotropic effects of IL-6  may
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be restricted to the stimulation of osteoclast formation from precursors in the 
bone marrow (Roodman, 1992).
Human osteoblast-like cells derived from trabecular bone produce 
bioactive TNF in response to stimulation by IL-1, bacterial 
lipopolysaccharide (LPS) and granulocyte/macrophage colony-stimulating 
factor (GM-CSF). IL-1, at an optimal concentration of 10U/ml, was as potent 
as LPS in inducing TNF production. The osteotropic hormones 1.25D, PTH 
and calcitonin did not affect TNF release in this model (Gowen etal, 1990). 
The constitutive production of both TNF and IL-1 by human osteoblasts is 
minimal but the cells are stimulated to produce IL-1 by both TNF and LPS. 
The hormones PTH and oestradiol were shown to have no effect on either 
constitutive or TNF induced IL-1 release (Keeting etal, 1991a). Human 
trabecular bone derived cells produce IL-6  in response to LPS, TNF and IL-1 
(Linkhart etal, 1991; Littlewood etal, 1991b). PTH enhances IL-6  
production in ROS 17/2.8 cells but has no effect on the production of IL-6  by 
primary cultures of human osteoblasts. These reports would suggest that 
locally produced cytokines in the bone microenvironment may be regulated 
by other cytokines and local factors independently of the hormone status of 
the individual. One possible exception to this is TGFp, a component of bone 
matrix with potent effects on the growth and differentiation of many cell types 
(chapter 1, 1.6.2(d)). Oestradiol and PTH enhance TGFp mRNA in human 
osteoblast-1 ike cells (Merry etal, 1991) and oestradiol enhances TGFp 
production (Oursler etal, 1991). Oestradiol has also been reported to inhibit 
the release of IL-1-induced TNF from adult human osteoblasts (Rickard, 
Russell and Gowen, 1992).
BOP cells were assessed for their ability to produce cytokines 
characteristic of primary cultures of trabecular bone cells. Seven BOP cell 
lines were treated with TNF, IL-1 and oestradiol and their production of IL-6 , 
IL-1 and TNF assayed. The effect of IL-1 a treatment on IL-1 p mRNA
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Cells were seeded at 4X104 per well of 24 well plates in phenol red-free 
defined medium and treated with1 0 U/ml recombinant human (rh) IL-1 a, 
1 ,0 0 0 U/ml rhTNFa, or 1 0_9M 17p oestradiol (E2) for 72h. Triplicate wells 
were set up and results are expressed ± SEM. Fresh conditioned media 
were assessed for IL-6  content using the B9 assay and for TNF production 
utilising the WEHI bioassay. Aliquots of conditioned media were stored at - 
20°C and subsequently assayed for interleukin 1 content using DION4 M 
cells, and for TNF by immunoradiometric assay (IRMA).
IL-6  bioassav
IL-6  was measured by specific bioassay utilising an IL-6  dependent 
hybridoma cell line B9 (Helle etal, 1988). B9 cells proliferate in response to 
IL-6  but do not respond to other cytokines except for a small response to 
murine IL-4. Proliferation of the cells is quantified by addition of 3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). Uptake of this 
dye measures the overall metabolic activity of the cells.
B9 cells were maintained in RPMI-1640 medium supplemented with 5% 
FCS, 100U/ml penicillin, 1 0 0ng/ml streptomycin, 2 mM L-glutamine, 5X10*5M 
2 -mercaptoethanol and 0 .1% (v/v) monocyte conditioned medium (a source 
of IL-6 ).
For the assay, B9 cells were washed twice in complete RPMI lacking the 
IL-6  and seeded at 5000 cells per microtitre well. Cells were cultured for 72h 
with 10Ofxl medium and 10Ojxl samples or known amounts of rhlL-6 . Serial 
dilutions of 100, 30, 10,1, 0.1 and 0 U/ml of hrlL-6  were prepared for the 
standard curve. Cells were incubated for 72h, 50mg/ml of MTT in PBS (20^ 1
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per well) was added 4h before the end of the culture period. Medium was 
then aspirated and replaced with 1 OOjj.1 of 0.04M HCI in propan-2-ol to 
dissolve the metabolised dye. Samples were measured 
spectrophotometrically using a Dynatech micro-ELISA reader with 570nm 
and 630nm as test and standard wavelengths respectively. OD570-630 was 
plotted against standard concentrations to generate a standard curve.
Sample OD570-630 was used to quantify the amount of IL-6 in the conditioned 
medium.
D10Nj_M assay for IL-1
IL-1 production was assayed using the DION4M murine T cell line.
DION4 M cells proliferate in response to IL-1 and are responsive, but to a 
lesser extent, to IL-2 and murine IL-4. Cells were maintained in RPMI + 10% 
FCS, rhlL-2  (20U/ml), concanavalin A (5ng/ml) and 2-mercaptoethanol 
(5X10_5M). For the assay, cells were seeded at 104 per well of 96-well plates 
in medium with concanavalin A and saturating levels of IL-2 (20U/mI). This 
last masks the response to any IL-2 present in the samples and also 
increases sensitivity to IL-1. A standard curve was prepared by serial dilution 
to give standards of 10, 1, 0.1, 0.03, 0.01, 0.003, 0 .001  U/ml rhlL-1a. For the 
last 18h of a 72h culture cells were pulsed with 1 »xCi per well of tritiated 
thymidine (3H-Tdr). At the end of the culture period cells were harvested onto 
filter paper using a cell harvester (Skatron instruments, Norway). The amount 
of incorporated radioactivity was measured using a Rackbeta scintillation 
counter (LKB-Pharmacia, Uppsala, Sweden). Results were extrapolated from 
a plot of log-io concentration of standard against counts per minute (CPM). 
Results are expressed as ng/ml.
WEHI assay
Bioactive TNF in the conditioned media of BOP cells treated with IL-1 and 
oestradiol was assayed using the murine fibrosarcoma cell line WEH1164 
clone 13. These cells are lysed by TNFa and p. WEHI cells were maintained
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in RPM11640 + 10% FCS. For the assay cells were dispersed with trypsin, 
centrifuged and resuspended in 1 0 ml of complete RPMI. Cells were seeded 
at 2X104 per microtitre well in a volume of 100^1 and allowed to settle for 4h 
at 37°C. 100|xl of rhTNFa standards prepared to give final concentrations of 
0. 0.001, 0.01, 0.1,1,10, 100 and 1,000U/ml were added to wells in triplicate. 
Samples were added in quadruplicate and plates were incubated for 24h at 
37°C. 10 jil of MTT solution (5mg/ml in PBS) were added to each well and 
plates incubated for a further 4h. The medium was then aspirated with a 
syringe and 5 0 jj.I of isopropanol containing 0.04M HCI added to dissolve the 
MTT. Absorbance was read at reference and test wavelengths of 630nm and 
570nm respectively. A standard curve of percentage cytotoxicity (1-[OD 
sample/OD zero standard] X100) vs TNF concentration was plotted, the 
percentage cytotoxicity was calculated for each sample and the 
corresponding TNF concentration extrapolated from the standard curve.
TNF IRMA
TNFa in BOP cell conditioned media was measured using a specific 
immunoradiometric assay. In this assay several monoclonal antibodies 
directed against distinct epitopes of TNFa are coated on the lower and inner 
surface of plastic tubes. Standards or samples are added to the tubes and 
will show affinity for the antibodies. The signal antibody is labelled with 125l 
and triggers the immunological reaction. After washing, the remaining 
radioactivity bound to the tube reflects the antigen concentration.
2 0 0 |j.l of sample or standard were dispensed into the precoated tubes and 
50jil of tracer added. Tubes were incubated for 18h at room temperature, 
then the contents aspirated. Tubes were washed and counted using a 
gamma counter. A graph of log-io concentration (abscissa) vs CPM 
(ordinate) was plotted and results extrapolated.
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Expression of cvtokine mRNA
Cells in 1 0 0 mm culture dishes were incubated for 24h with phenol-red free 
defined medium then treated for 6 h with fresh medium with or without rhlL- 
1 a (1 OU/ml) or for 9h with 10_9M 17p oestradiol. RNA was extracted and 
subjected to slot blot analysis.
SlpLfrlQt..angly§js
For slot blot analysis 10^g per sample of RNA were diluted to 50jxl with 
DEPC water and 50)xl of formamide added. RNA samples were denatured 
by incubation at 65°C for 1 0 min followed by quenching on ice. 8^13M 
sodium acetate were added and samples were diluted to 5^g/100^l with a 
solution of 50% formamide and 0.25M sodium acetate (solution A). 2-fold 
serial dilutions of the samples were made in solution A in microtitre wells 
and kept on ice.
The manifold slot blot apparatus was soaked in DEPC water for 30min 
prior to use. The Hybond-N+ filter was presoaked first with water then with 
2X SSC and the manifold assembled. 100^1 of each sample were blotted 
onto the filter by applying a vacuum. 100nl of solution A was then added to 
each slot. Filters were fixed with 50mM NaOH, rinsed in 2 X SSC, and stored 
wrapped in saran wrap at <4°C.
Filters of RNA from control and IL-1 a treated cells were hybridised with a 
cDNA probe for IL-1 p, and filters of RNA from 17p oestradiol treated cells 
were probed for TGFp. Hybridisation of filters and autoradiography were 
carried out as described in chapter 2 . The intensity of each slot on the 
autoradiographs was assessed using a Digit-X densitometer.
5.3 RESULTS
Interleukin 6  production bv BOP cells
Seven BOP cell lines were assessed for their ability to produce bioactive 
IL-6  constitutively and in response to IL-1 , TNF and oestradiol. IL-1 induced
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IL-6  production is shown in table 5.1, all seven cell lines were capable of 
secreting IL-6  but levels varied between experiments and between different 
cell lines. Constitutive and inducible IL-6  levels were lower in experiment 2. 
IL-6  production was enhanced to varying degrees by IL-1 in all seven cell 
lines, for example in experiment 1 BOP 7 responded to IL-1 with a 15-fold 
increase in IL-6  production, a 72 fold increase was observed in BOP 37. 
Certain cell lines, for example BOP 31, 37 and 70, also responded to TNF 
with enhanced IL-6  activity as shown in table 5.2. Treatment of the cells with 
17p-oestradiol for 72h had no effect on the IL-6  production by the cells 
(Table 5.3).
Interleukin 1 production
The production of bioactive IL-1 by the cells is shown in table 5.4. 
Constitutive production of IL-1 by all seven cell lines was very low but was 
considerably increased by treatment of the cells with TNFa. BOP 7 and 31, 
for example, displayed a greater response to TNF than cell lines 37 and 12. 
Oestradiol had no effect on the constitutive IL-1 production of any of the BOP 
cell lines tested.
TNF production
The production of TNF by BOP cells was assayed in two separate 
experiments. In one experiment conditioned media were stored at -20°C for 
the subsequent analysis of TNFa content by IRMA. In a second experiment 
fresh BOP cell conditioned media were assayed directly for bioactive TNF 
using the sensitive WEHI cell line. All seven cell lines produced high levels 
of immunoreactive TNFa (Table 5.5) and this production was not affected by 
treatment of the cells with IL-1 . Oestradiol had no effect on the TNFa 
secretion in six cell lines but caused a small increase in the amount of TNFa 
produced by cell line BOP 7. TNF produced by the cells was not bioactive, 
no cytotoxic effect was observed when conditioned media were assayed 
using the WEHI cell line.
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Expression of IL-1 B and TGFb mRNA 
The expression of mRNA for IL-1 p in control and IL-1 a treated cells is 
shown in Fig 5.1. Treatment with rhlL-1a for 6 h enhanced mRNA for IL-1 p in 
six cell lines, the greatest responses were seen in BOP 31 and 37. 
Constitutive expression of TGFp mRNA was very low (Fig. 5.2). E2 had no 
effect on the expression of TGFp mRNA by BOP cells. The relative slot blot 
intensities for cytokine/p-actin mRNA are shown in table 5.6.
128
BOP Control IL-1 ot m
MOU/mh
7 13 ±1 150 ±30.5 15
1 2 673± 175 1800 ± 0 2.7
26 14 ±2.4 103 ± 3 7.4
31 11 ±0.3 > 1 0 0  <1 ,0 0 0 -
33 12.3 ±2.3 < 1 0 0 -
37 130 ± 17.3 9333 ± 1667 72




7 < 1 0 11.7 ± 1.7
12 < 1 0 205 ± 58
26 < 1 0 198 ±58
31 < 1 0 115 ± 15
33 < 1 0 89 ±41
37 < 1 0 15 ± 1
70 < 1 0 10.3 ±0.3
(b). Experiment 2
Table 5.1 IL-6  production (U/ml) in BOP cells. Cells were treated with IL- 
1a for 72h and IL-6  in conditioned media assayed using the B9 hybridoma 
cell line. T/C is the ratio of treated to control values. Values for the same 
conditioned media are shown in Tables 5.2 and 5.3.
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BQP Control TNFa 
1 .0 0 0  U/ml
I ISl
7 13 ± 1 2 0  ± 2 .6 1.54
1 2 673± 175 1117 ± 101 1 .6 6
26 14 ±2.4 18 ±4.3 1.3
31 11 ± 0.3 127 ±14.5 11.5
33 12.3 ±2.3 20 ± 2.3 1 .6
37 130 ± 17.3 1117 ±242 8 .6




7 < 1 0 11.7 ± 1.7
12 < 1 0 205 ± 84
26 < 1 0 137 ±22
31 < 1 0 235 ± 35
33 < 1 0 33 ±12
37 < 1 0 17 ± 3
70 < 1 0 10.3 ±0.3
(b). Experiment 2
Table 5.2 IL-6 production in BOP cells treated with 1 .OOOU/ml TNFa for 
72h.
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7 13 ± 1 13 ± 1.5 < 1 0 < 1 0
1 2 673± 175 357 ± 64.4 < 1 0 < 1 0
26 14 ±2.4 12 ± 2 < 1 0 < 1 0
31 11 ±0.3 19 ±2.5 < 1 0 < 1 0
33 12.3 ±2.3 < 1 0 < 1 0 < 1 0
37 130 ± 17.3 147 ±37 < 1 0 < 1 0
70 120 ± 15.3 247 ± 62 < 1 0 < 1 0
Table 5.3 IL-6  production (U/ml) in cells treated with 10'9M 17p oestradiol 
for 72h. These are the same conditioned media as in Tables 5.1 and 5.2.
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BOP Control TNFa m
7 0.01± 0.004 0.26 ± 0.08 26 0 .0 0
1 2 0.07 ±0.01 0.11 ± 0 .0 2 1 .6 0.07 ±  0.004
26 0 .0 0 0.1 ±0.007 - 0.01  ±  0.006
31 0.02 ±  0.003 0.3 ± 0.15 15 0 .0 0
33 0 .0 2  ±  0.006 0.14 ±0.02 7 0 .0 2  ±  0.01
37 0.06 ±  0.01 0.154 ±0.04 2 .6 0 .11  ±0.06
70 0.1 ± 0 .0 2 0.466 ± 0.03 4.7 0.08 ± 0.01
Table 5.4 IL-1 prodution (U/ml) by BOP cells treated with 1,000U/ml 
rhTNFaor 10_9M 17- p oestradiol (E2) for 72h. Conditioned media were 
assayed for IL-1 using the DION4 M assay.
POP Control M b £ 2
7 7.48 ±0.08 6.94 ± 0.32 9.16 ±0.09
12 4.27 ±  0.46 4.95 ± 0.44 5.24 ±0.4
26 6.47 ±0.34 6.53 ± 0.07 5.71 ±0.18
31 6.45 ±0.18 7.26 ±013 7.38 ±0.55
33 7.6 ±0.38 9.35 ± 0.37 7.62 ±0.3
37 8.44 ±0.5 9.15 ± 0.17 7.77 ±0.7
70 5.36 ±0.2 5.9 ± 0.3 5.41 ±0.15
Table 5.5 TN Fa production (U/ml) by BOP cells treated in defined 
medium with 10U/ml rhlL-1aor 10_9M 17- p oestradiol (E2) for 72h. 
Conditioned media were assayed for TN Fa using an immunoradiometric 
assay.
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Fig. 5.1 (a). Interleukin ip mRNA expression in control and IL-1 a treated
BOP cells. Cells were incubated with 10U/ml IL-1 a for 6h and RNA extracted
as described in chapter 2. 5^g of RNA were loaded in the first slots as
indicated and 3 serial dilutions of each sample were loaded. Slot blots were
hybridised with a cDNA probe recognising IL-1 p. Equal loading of the RNA
was confirmed by probing stripped filters for human p actin (b) (next page).
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Fig. 5.2 (a). TGFp mRNA expression in six BOP cell lines treated with








Fig. 5.2 (b). Actin control.
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Table 5.6 Relative slot blot densities for IL-lp/p-actin (a) and TGFp/p-actin 
(b) mRNA normalised as 1.0 for the ratio of densities obtained with mRNA 
from unstimulated cells.
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g r4 D ISCU SS ION
Cytokines such as IL-1, IL-6  and TNF may be important osteotropic agents 
and are produced by osteoblast-like cells in vitro. The ability of SV40- 
immortalised osteoblasts to produce cytokines and to display the cytokine 
responsiveness characteristic of parent cultures was studied. Oestrogen 
deficiency is strongly linked to the development of postmenopausal 
osteoporosis but the mechanism of oestrogen action remains undefined. A 
potential role for oestrogen as a regulator of cytokine production has been 
suggested by Pacifici et a /(1989) and oestradiol may regulate cytokine 
release by osteoblasts (Rickard, Russell and Gowen, 1992). The effects of 
oestradiol on the basal production of IL-1 , IL-6  and TNF by BOP cells and on 
the expression of TGFp mRNA in the cell lines was assessed.
Littlewood et al (1991b) report that primary cultures of human osteoblasts 
produce high levels (1000-2050 U/ml) of IL-6  constitutively and the release 
of IL-6  is dramatically increased by treatment with IL-1 and TNF. The 
amount of IL-6  released by unstimulated BOP cells was much lower but the 
cells were capable of responding to IL-1 and TNF with enhanced IL-6  
production. The low levels of constitutive IL-6  in BOP cells are similar to 
those produced by the human osteosarcoma cell lines MG-63 and HOS 
TE85, two cell lines which also respond to IL-1 and TNF with enhanced IL-6  
production (van Damme etal, 1987; Rickard, Clover and Gowen manuscript 
in preparation). Linkhart et ai (1991) describe the secretion of IL-6  by cells 
isolated from normal human bone and report no detectable constitutive IL-6  
activity but secretion was induced by IL-1. The differences in basal IL-6  
release observed for primary cultures may reflect the heterogeneity and 
variable growth rate of cells derived from different sources. Treatment of 
BOP cells with 17p-oestradiol did not affect the basal release of IL-6  in any of 
the cell lines tested. Similarly, Rickard, Russell and Gowen (1992) report no
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consistent effect of oestradiol on either basal or stimulated IL-6  release in 
primary cultures of human osteoblasts.
BOP cells released high levels of TNF constitutively, much higher than the 
reported values of 0-0.25U/ml for primary cultures (Gowen et al, 1990). IL-1 
had no effect on TNF release by BOP cells. Oestradiol inhibits the IL-1 - 
induced TNF production of trabecular bone-derived cells (Rickard, Russell 
and Gowen, 1992) but the hormone had no effect on the constitutive release 
of TNF in six of the BOP cell lines tested. In cell line BOP 7, oestradiol 
caused a slight enhancement of TNF production. This cell line may 
represent a subpopulation of oestrogen responsive cells that were present 
in the parent cultures. The TNF produced by the cells was found to be 
immunoreactive but not bioactive. One possible explanation for this is the 
production of natural inhibitors of TNF. A human inhibitor of TN Fa has been 
purified from the urine of febrile patients and the inhibitor can be measured 
in an assay of cytotoxicity using a TNF-susceptible cell line (Seckinger,
Isaaz and Dayer, 1988). A soluble form of the 55kDa TNF receptor exists 
which binds free TNF and inhibits its interaction with cell-surface receptors 
(Schall etal, 1990). The enhanced constitutive production of TNF by BOP 
cells may be caused by upregulation following SV40-induced transformation 
and this excessive production of TNF may give rise to the secretion of 
natural inhibitors.
BOP cells produced low levels of IL-1 constitutively and responded to TNF 
by enhanced release of IL-1. Treatment with IL-1a also enhanced 
expression of mRNA for IL-1 p suggesting autocrine regulation in the cell 
lines as has been observed for primary cultures of trabecular bone cells 
(Merry etal, 1991). The immortalised cell lines displayed low constitutive 
expression of TGFp mRNA and oestradiol did not enhance this specific 
mRNA unlike the effect of oestradiol that has been reported for primary 
cultures (Oursler et al, 1991).
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BOP cell lines display the characteristics of mature osteoblasts with 
respect to alkaline phosphatase activity and production of bone-associated 
proteins. The immortalised cell lines were also capable of responding to 
both IL-1 and TNF with enhanced IL-6  production, and responded to TNF 
with enhanced IL-1 production as has been reported for primary cultures of 
osteoblast-like cells. The high levels of TNF produced by the cell lines may 
be a result of the SV40-induced transformation process. The cell lines failed 
to respond to oestradiol with enhanced TGFp mRNA expression but one cell 
line, BOP 7, displayed enhanced TNF release when treated with oestradiol 
and may represent a subpopulation of oestrogen-responsive cells present in 
the original parent cultures.
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CHAPTER 6




Cell lines obtained by transfection of primary cultures with SV40 commonly 
display an extended lifespan in vitro but eventually the cells senesce. BOP 
cells express many features of the parent cultures of osteoblast-like cells. 
The stability of this phenotypic expression was explored by assessing 
alkaline phosphatase activity and osteocalcin production as a function of 
time in culture. BOP 12 showed high ALP activity and a functional response 
to 1,25D for up to 15 passages but reduced ALP activity at passages 18 and 
19; osteocalcin production was maintained to passage 18 but lost at 
passage 19. Similarly, BOP 26 showed reduced ALP activity at passage18 
but osteocalcin production was maintained. BOP 7 was stable for 13 
passages. Expression of SV40 T antigens was persistant in BOP 12 to 
passage 18. The loss of phenotypic expression by the cells may be a 
reflection of the crisis stage that is a characteristic of SV40 transformed cells.
6.1 INTRODUCTION
An important consideration when using a cell line for in vitro studies is the 
stability of the phenotype as cells are continuously maintained and 
subcultured. Human trabecular bone-derived cells have only a limited 
lifespan in vitro. Primary cultures of a variety of cell types, when transfected 
with SV40, commonly yield cell lines which display an extended lifespan 
and express the phenotype of the parent cultures. However, little 
information is available concerning the long-term stability of phenotypic 
expression by the transformed cell type.
Pinet eta l (1985) transfected human juxtaglomerular cells with SV40 DNA 
and obtained three cell lines that retained the ability to secrete the hormone 
renin. The quantity of renin produced declined after the first and second 
subcultures but then remained stable for the following five subcultures. 
Singer eta l (1987) used SV40 to transform human bone marrow stromal
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cells and obtained clonal cell lines that persistantly contained both round 
(haemopoietic) cells and adherent (stromal) cells. The stromal cells 
synthesised proteins characteristic of the parent cells, such as interstitial and 
basal lamina collagens, muscle-type actin, vimentin and thrombospondin. 
The cell lines survived up to 36 passages (11 months in culture) but no data 
is presented detailing the persistance of the characteristic proteins with time 
in culture. In a subsequent paper, Nemunaitis e ta l (1989) described the 
production of colony stimulating factors by round cells of the same series of 
cell lines. If cells were stimulated with IL-1a or p, or TNFathey produced 
high levels of colony stimulating factors which were detectable for up to 16 
passages.
Other authors describing the transfection of rabbit kidney cells with SV40 
early region genes demonstrate the ability of transformed cells to express 
the characteristics of parent cells (Scott etal, 1986). The cell lines obtained 
were capable of an extended life with continued expression of the 
phenotype. Similarly, transformation of neonatal rat Schwann cells resulted 
in a cell line with established Schwann cell properties (the ability to 
synthesise sulphogalactosyl ceramide and express mRNA for for the myelin 
protein Po) which could be maintained for 180 doublings (Tennekoon etal,
1987). Two bone cell lines were established from rat calvarial osteoblasts 
by immortalisation with SV40 large T antigen and the neomycin resistance 
gene. One cell line, RCT-3, constitutively expressed markers of the 
osteoblast phenotype. The cells possessed alkaline phosphatase activity, 
expressed mRNA for type I collagen and osteopontin and displayed a PTH 
responsive adenylate cyclase. A second cell line, RCT-1, could be induced 
to express the above characteristics by treatment with retinoic acid (Heath et 
al, 1989). These cells have a limited lifespan in vitro (Baron, personal 
communication).
143
Keeting eta l (1992) transformed primary cultures of trabecular bone cells 
with a vector incorporating SV40 early region genes and resistance to the 
antibiotics neomycin and G418. The cell line obtained grew rapidly but 
slowed after eight passages, cells entered crisis and became senescent 
between passages 12 and 14. The pX-8 SV40 vector used to produce BOP 
cells had been used to transfect pancreatic p islet cells, the cell line obtained 
secreted insulin for eight passages and then stopped releasing the hormone 
(Marini and Soldevila, personal communication).
In order to assess the stability of the phenotype of immortalised BOP cells, 
and to define the useful lifespan of the cell lines, three lines were 
subcultured continuously and characterised for two markers of the 
osteoblast phenotype at regular intervals. The ability of the cells to continue 
producing SV40 T antigens with time in culture was also monitored.
6.2 METHODS
Cell lines BOP 7, 12 and 26 were maintained in continuous culture and 
assayed for control and 1,25D responsive alkaline phosphatase activity and 
osteocalcin production at every second or third passage until the cells 
entered crisis and failed to grow. Cells were seeded at 4X104/ml in 24-well 
plates, allowed to settle for 24h and treated with ethanol vehicle or 10_8M 
1,25D for 48h. Conditioned media were assayed for osteocalcin production 
and cell layers for ALP activity as detailed in chapter 2. Triplicate wells were 
assayed and results expressed ± SEM.
At passages 10,13,15 and 18, cells of BOP 12 were seeded onto poly-L- 
lysine treated glass slides, allowed to settle for 24h, then fixed and stained 




After approximately 15 passages in vitro, BOP cells failed to attain 
confluence and many cells were shed into the medium. The remaining cells 
continued dividing when passaged and seeded into fresh medium but after 
approximately 19/20 passages the cells failed to grow and sparse cells with 
the morphological appearance shown in figure 6.1 remained in the culture 
dishes. The remaining cells were large, irregular in shape and granular in 
appearance.
Alkaline phosphatase expression 
The alkaline phosphatase activity of cell line BOP 12 maintained in 
continuous culture and assayed every few passages is shown in table 6.1. 
Constitutive ALP activity was stable for 17 passages but was reduced at 
passage 18 and 19. The cells responded to 1.25D with enhanced ALP 
activity with the greatest response seen at passages 10 and 12 and a 
reduced response at passage 19. BOP 26 (Table 6.2a) showed a decline in 
ALP activity with time in culture but responsiveness to 1,25D was 
maintained. BOP 7 was stable for 13 passages (Table 6.2b).
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POP Control 1 .2 5 D m
(a1 12p10 1.48 ±0.18 5.20 ± 0.25 3.5
12p13 1.68 ±0.21 3.62 ± 0.25 2.15
12p15 2.62 ±0.21 5.08 ± 0.50 1.94
12p17 1.09 ±0.04 1.92 ±0.08 1.76
12p18 0.12 ±0.02 0.29 ± 0.02 2.42
12p12 1.02 ±0.02 3.3 ±0.2 3.24
12p17 1.24 ±0.15 1.92 ±0.11 1.55
12p19 <0.50 0.7 ± 0.05 1.4
Table 6.1 Alkaline phosphatase activity in control and 1,25D treated BOP 
12 assayed at different passages throughout continuous culture, (a) and (b) 





BOP Control 1.25D T/C
Xal 26p12 2.46 ±0.3 5.55 ±0.37 2.26
26p15 1.05 ±0.04 2.6 ±0.16 2.48
26p18________ 0.12 ±0.02______ 0.24 ± 0.02__________ 2 _
Xbi 7p8 <0.50 0.68 ±0.05 1.36
7p12 0.58 ± 0.02 1.42 ±0.05 2.45
7p13 <0.50 0.75 ±0.05 1.5
Table 6.2 Alkaline phosphatse activity in (a) BOP 26 and (b) BOP 7 
assayed at different passages.
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Osteocalcin production 
None of the cell lines produced constitutive osteocalcin but production was 
induced by 1.25D. Osteocalcin production by BOP 12 was greatest at 
passage 10 and then declined, cells at passage 19 failed to synthesise 
osteocalcin (Table 6.3). BOP 26 cells produced similar levels of osteocalcin 
at the three time points assayed. Osteocalcin production was low in BOP 7 
and the low levels were maintained to passage 13 (Table 6.4).
T antigen production 
The production of SV40 T antigens by cells of BOP 12 at different 
passages is shown in figure 6.2. Cells displayed positive nuclear staining 
with the antibody at early passage (p10) and cells continued to produce T 











12p12 2.69 ± 0.30
12p17 1.16 ± 0.30
12p19 0
Table 6.3 Osteocalcin production in cells of BOP 12 treated with 1,25D at 





{a) 26p12 3.47 ±  0.09
26p15 2.4 ± 0.11
26p18________ 2.45 ± 0.32
7p8 1.52 ±  0.1
7p12 0.6 ± 0 . 3
7p13 1.85 ± 0.03
Table 6.4 Osteocalcin production in (a) BOP 26 and (b) BOP 7 cells 
treated with 1,25D at different passages.
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Fig. 6.2 (overleaf) Expression of SV40 T antigen in cells of BOP 12.





The phenotype of the osteoblast-like cell lines was stable for a limited 
number of passages, after passage 15/16 expression of the osteoblast 
characteristics alkaline phosphatase activity and osteocalcin production was 
reduced or lost. A fall in the responsiveness of cells to 1,25D may be a 
result of a loss of functional 1,25D receptors in cells undergoing or about to 
enter the crisis state. Cells transfected with SV40 DNA typically divide for 
many generations beyond the expected lifespan of the parent primary 
cultures. The cell lines (described as "pre-immortalised" by Huschtscha and 
Holliday, 1983) then undergo a period of crisis, cells are shed into the 
medium and the remaining adherent cells fail to divide and ultimately 
senesce. The BOP cell lines, when initially isolated, were capable of post­
confluent growth and formed multilayered foci (Chapter 3, Fig. 3.3) which 
persisted for a number of passages in culture. After 12-15 passages 
confluent cells in 100mm dishes did not form foci but were shed into the 
medium and by passage 17 cells failed to grow to confluence. Remaining 
cells were able to grow sufficiently for a further two subcultures but with 
smaller yields of cells. The cells appeared to be senescent by passage 19. 
Production of T antigen persisted in the cells to passage 18, suggesting that 
the decline of phenotypic expression by the cells, or the crisis state, was not 
due to a loss of the transforming vector or a failure of early gene 
transcription.
The pX-8 vector used to transfect primary cultures of osteoblasts contained 
an origin-defective SV40 early region, 8 regions at the Bgl I site were 
removed and replaced by a Xho I linker (Fromm and Berg, 1982; see Fig 
3.2). The portion of DNA lost from the pX-8 vector contains binding regions 
for the large T antigen. In wild-type vectors, T antigen is able to bind to the 
origin of replication and autoregulates early region gene expression by 
inhibition of transcription initiation (Myers etal, 1981). T antigen is
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overproduced in cells which have stably incorporated an origin defective 
SV40 vector and this may account for the enhanced transformation 
efficiency of ori- observed by Small, Gluzman and Ozer (1982).
The precise mechanism of T antigen-induced mitosis of transfected cells is 
not known but the protein has been shown to stimulate chromatin replication 
in epithelioid cells (Graessman and Graessmann, 1976). T antigen, when 
injected into the cytoplasm of recipient cells, migrates across the nuclear 
membrane and stimulates cellular DNA synthesis (Tjian, Fey and 
Graessmann, 1978). In addition, large T antigen, purified from SV40- 
transformed human fibroblasts, exhibits ATPase activity which is enhanced 
severalfold by the DNA homopolymer poly (dT) (Giacherio and Hager,
1979). The ability of T antigen to bind both double stranded and single 
stranded DNA and its nucleic acid-stimulated ATPase suggests a role for T 
antigen in initiation of DNA synthesis by separating double stranded DNA 
and binding to the single strands to prevent reforming of the double helix. T 
antigen is able to block differentiation in preadipocytes by suppressing the 
expression of adipocyte differentiation-dependent genes (Cherington etal,
1988). BOP cells were capable of differentiation in response to 1.25D but 
gradually lost this ability, prolonged overexpression of T antigen may have 
resulted in prevention of the cells from differentiating. However, the clonal 
cell lines 37WW3 and 37WW8 described in chapter 3, which may represent 
stable post-crisis lines, displayed high alkaline phosphatase activity and 
responsiveness to 1,25D. The loss of phenotype of the pre-immortalised cell 
lines may be a function of the crisis stage which is so characteristic of SV40- 
transfected cells. Oshima et a /(1977) observed no differences between 
precrisis and postcrisis cell lines with respect to growth rate, ability to form 
colonies on confluent monolayers or production of T antigen. The majority of 
cells do not survive crisis but the small number that are able to form post-
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crisis lines may do so by continually producing stimulatory factors making 
them capable of unlimited growth.
It is interesting to note that BOP cells have a longer lifespan in culture of 
19/20 passages (approximately 120 generations) than the immortalised 
osteoblastic cell line HOBIT which survives for more than 80 generations 
(Keeting etal, 1992). This may reflect the age of the donors used, BOP cells 
are derived from a 17 year old male, HOBIT cells from a 68 year old female. 
Primary cultures of osteoblasts obtained from young donors grow more 
rapidly in vitro than those from elderly patients and attain confluence more 
quickly. Oshima e ta l(1977) have suggested that the crisis stage of 
immortalised cells is a reflection of the limited lifespan of normal human 
diploid fibroblasts as the onset of crisis is shorter for cells infected near the 
end of their normal lifespan in culture. BOP cells may thus survive longer 
because the original primary cultures were transfected early in their normal 
life.
BOP cell lines obtained by transfection of primary cultures with SV40 DNA 
displayed a stable phenotype for 15 passages in vitro. A reduction of 
alkaline phosphatase activity and osteocalcin production, and a reduced 
response to 1,25D, were observed in cells maintained for more than 15 
passages. This loss of phenotype coincided with shedding of cells into the 
medium and their ultimate senescence. The crisis stage of BOP cells did not 
appear to be a result of a loss of T antigen expression as the cells continued 





7, . gE N E R A l PISCVSSION
7.1 Immortalisation of primary cultures
Transfection of primary cultures of human osteoblasts with SV40 DNA 
yielded populations of cells with a capacity for rapid growth, large numbers 
of cells could be obtained which expressed hallmarks of the osteoblast 
phenotype. The phenotype of the cells was stable for 15 passages and then 
declined, cells were shed into the medium and the remaining cells ultimately 
senesced. Two cell lines which survived limiting dilution cloning may 
represent stable, post-crisis cell lines. Oshima et a /(1977) have 
demonstrated that SV40 transformed human fibroblasts have a different 
DNA content per cell than precrisis cells and Huschtscha and Holliday 
(1983) observed that post-crisis cell lines contained a very high percentage 
of hyper-diploid cells. Oshima et al have suggested that the recovery of a 
post-crisis cell line depends upon the formation of a small number of variant 
cells. Picking single transformed foci and subsequent recloning before 
crisis, as has been done for this thesis, would reduce the chance of 
obtaining a long-term immortalised cell line if recovery from crisis was 
acheived by a small number of cells with an altered genetic complement. 
Growing bulk cultures of cells and maintaining them until post-crisis cells 
emerge may be a more efficient method of obtaining a long-term cell line.
Mayne et a /(1986) transfected human fibroblasts with a plasmid 
containing both SV40 early regions and the bacterial gene gpt and reported 
that use of the selectable marker increased the probability of establishing an 
immortal cell line. However, these authors report that all transfected cells 
were maintained in bulk cultures and one cell line was obtained from each 
culture as would be expected. Other workers using antibiotic resistance 
genes as selectable markers have obtained cell lines with a limited growth 
potential but do not report the successful maintenance of long-term cell lines 
derived from senescent cultures (Heath etal, 1989; Keeting etal, 1992).
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Scott et a /(1989) have demonstrated that the neoplastic phenotype of 
SV40 transformed cells can be suppressed by inducing nonterminal 
differentiation. These workers obtained an adipocytic cell line by 
transfection of murine mesenchymal stem cells with SV40 DNA. Culturing 
the cells in heparinised DMEM containing 25% human plasma induced the 
cells to revert to a nontransformed state and repressed expression of the 
large T antigen. Cells that had been induced to nonterminally differentiate 
failed to form colonies in semi-solid medium. This may be a potentially 
useful mechanism for controlling the growth of immortalised cell lines and 
allowing the normal processes of differentiation to go ahead. Use of a vector 
coding for a mutant temperature-labile T antigen to transfect cells is another 
potential mechanism for controlling the transformed phenotype of the 
immortalised cell lines. Cells transfected with this mutant T antigen when 
maintained at 39°C failed to form colonies and the transformed phenotype 
was repressed (Radna etal, 1989). The disadvantage of using this 
technique is the abnormal temperature required to inhibit T antigen 
production which may also affect other cell functions.
The senescence of cells transfected with SV40 DNA may be related to the 
limited growth potential of the parent primary cultures. BOP cells that had 
been preserved in liquid nitrogen and subsequently revived had similar 
growth properties and phenotypic characteristics to cells prior to 
cryopreservation, but cell lines persistantly senesced after around 20 
passages irrespective of the stage at which they were frozen. It is possible 
that the programmed cell death of the cell lines was due to a loss of 
stimulation of the cells, perhaps due to a cessation of production of certain 
growth factors. Apoptosis in human monocytes is reported to be prevented 
by addition of stimulatory factors such as lipopolysaccharide, TNFa and IL-1p 
(Mangan, Welch and Wahl, 1991). Pre-crisis human fibroblastic cells were 
able to grow well in the medium from senescent cells (Oshima etal, 1977)
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but the ability of medium conditioned by pre-crisis cells to affect the growth of 
cells undergoing senescence has not been tested.
7.2 Phenotypic expression of immortalised cells.
Primary cultures of trabecular bone-derived cells are thought to contain 
osteoblasts at various stages of differentiation. It was initially proposed that 
the action of the transforming SV40 vector would be to "freeze" the cells at 
their particular stage of differentiation and produce a panel of cell lines 
representing different stages of the osteogenic pathway. Owen et al (1990) 
have described the progressive development of the rat osteoblast 
phenotype in vitro. Three principal stages occur, proliferation, extracellular 
matrix maturation and mineralisation. During the proliferative period there is 
a peak of DNA synthesis and enhanced expression of the H4 histone. Type 
I collagen, fibronectin and TGFp are actively expressed. Enhanced 
expression of alkaline phosphatase is observed immediately following the 
proliferative period, later on enhanced expression of osteocalcin and 
osteopontin occurs at the onset of mineralisation. Bianco et a /(1989) have 
shown that bone sialoprotein is produced late in the differentiation pathway. 
Developmental studies of the expression of bone matrix proteins suggest the 
sequence of events shown in figure 7.1 (Gehron Robey, personal 
communication). For BOP cells to represent each specific stage different cell 
lines would be expected to produce only those proteins occurring at each 
stage. In fact, with the possible exception of BOP 7 which produces very 
small amounts of osteocalcin, all BOP cells produce all the noncollagenous 
proteins assayed and all express mRNA for type I collagen. The 
developmental sequence of the osteoblast may be a gradient of 
differentiation necessary for the ordered production of a mineralised 
extracellular matrix rather than a series of specific steps. The ability of BOP 
cells to mimic in vitro the ordered developmental sequence of bone matrix
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Fig. 7.1 Production of matrix proteins in osteoblast differentiation
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formation has not been studied. The onset and progression of osteoblast 
differentiation are closely related to cell growth (Stein, Lian and Owen,
1990) and as the BOP cell lines have growth characteristics resembling a 
transformed rather than a normal phenotype they may not reproduce the 
normal sequence of events.
With respect to the expression of markers associated with the osteoblastic 
phenotype BOP cells resembled primary cultures of human osteoblast-like 
cells more closely than do osteosarcoma cell lines currently in use. For 
example, cells of the human osteosarcoma line MG-63 respond to 1,25D by 
producing osteocalcin but express very low levels of alkaline phosphatase. 
The human osteosarcoma cell line HOS TE85 have higher levels of alkaline 
phosphatase but fail to produce osteocalcin in response to 1,25D (Clover, 
personal communication). Another osteoblastic cell line, FM30, produces 
osteocalcin constitutively, in the absence of 1,25D suggesting that in this cell 
line the osteocalcin gene is upregulated as a result of the transformation 
process. BOP cells display the responses of normal osteoblasts to the 
calciotropic hormone 1,25D, are more readily available in large numbers 
than primary cultures, and may prove useful in establishing the effects of 
other hormones, such as glucocorticoids, on matrix production. The 
responses of BOP cells to the cytokines IL-1 and TNF followed a similar 
pattern to that observed with primary cultures. However, the cells produced 
abnormally high levels of TNF which may be related to their rapid growth 
rate.
7.3 Future studies
Other workers in this laboratory have raised a series of monoclonal 
antibodies against 1,25D treated primary cultures of human osteoblasts.
One antibody, OBL, reacts with osteoblasts lining the bone surface and also 
recognises plump osteoblasts which are actively forming bone in cryostat
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sections of human osteophyte tissue. A second antibody, OBM, is reactive 
with osteocytes. Antibody OBL recognised epitopes on the surface of HOS 
TE85 cells and reacted positively with BOP cell lines 7, 12, 26, 31 and 37. 
OBM reacted with only select cells of cell lines BOP 12, 26 and 31, and 
select cells of MG-63 and HOS TE85. These data demonstrate that BOP 
cells have similar antigenic components to osteoblasts in situ. As a source 
of a large number of cells expressing the osteoblast phenotype more closely 
than osteosarcoma cell lines BOP cells may be used to purify potential 
antigens recognised by the monoclonal antibodies.
Human osteoblasts are amenable to transfection by the calcium 
phosphate/DNA coprecipitation technique. It may be possible to retransfect 
cells with cDNA coding for certain matrix proteins and assess the effects of 
overproduction of the proteins on other aspects of cell function, such as cell 
adhesion and matrix mineralisation. Conversely, production of a particular 
matrix protein may be blocked by allowing the cells to internalise a specific 
antisense oligonucleotide, the effect of deprivation of certain matrix proteins 
could then be studied.
Turksen and Aubin (1991) have described the immunoselection of 
subpopulations of osteoprogenitor cells by fluorescence activated cell 
sorting (FACS) using a monoclonal antibody directed against alkaline 
phosphatase. Using monoclonal antibodies directed against osteoblast cell 
surface antigens it would be possible to isolate populations of cells 
responsive to specific hormones and growth factors. The ability of BOP cells 
to express receptors for oestradiol or PTH has not been tested. Cells within 
the population expressing the oestrogen receptor could potentially be 
isolated for the study of oestrogen effects. Isolation of subpopulations of 
cells expressing certain integrins may be useful for studying cell adhesion 
and may assist in the identification of the ligands bound by specific integrins.
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Primary cultures of human osteoblast-like cells were transfected with SV40 
DNA and a series of cell lines obtained. The cells expressed many of the 
hallmarks of the parent cultures and were able to differentiate in response to 
1,25D. The cells had a limited lifespan in vitro but were stable for 15 
passages. The cells displayed the responses of normal osteoblasts to the 
cytokines IL-1 and TNF but produced aberrant levels of inactive TNF. The 
cell lines resembled parent cultures more closely than the human 
osteosarcoma cell lines MG-63 and HOS TE85 and may prove to be a useful 
model for studying osteoblast function.
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